AD_____

Award Number: DAMD17-00-1-0583

TITLE: Mechanisms of Alcohol Induced Effects on Cellular
        Cholesterol Dynamics

PRINCIPAL INVESTIGATOR: W. Gibson Wood, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota
                           Minneapolis, Minnesota 55455-2070

REPORT DATE: September 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                        Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 2004	3. REPORT TYPE AND DATES COVERED Final (1 Sep 00 – 31 Aug 04)

4. TITLE AND SUBTITLE
Mechanisms of Alcohol Induced Effects on Cellular Cholesterol Dynamics

5. FUNDING NUMBERS
DAMD17-00-1-0583

6. AUTHOR(S)
W. Gibson Wood, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Minnesota
Minneapolis, Minnesota 55455-2070

E-Mail: Woodx002@umn.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES
Original contains color plates. All DTIC reproductions will be in black and white.

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

Cholesterol is important in regulation of cell structure and function. Equally important is the role that cholesterol plays in vascular disease. The focus of this grant has been on mechanisms of alcohol induced disruption of cellular cholesterol transport and distribution. We demonstrate that many of the systems involved in regulating cholesterol transport are perturbed by ethanol (HDL, apoA-I, LDL, PC-PLC, PC-PLD). The Golgi complex plays an important role in protein and lipid trafficking and our new data confirm that the Golgi complex is perturbed by ethanol. Moreover, we are now able to measure the distribution of cholesterol in the Golgi complex and we showed that ethanol induce movement of cholesterol out of the Golgi complex with a greater effect on the *cis*-medial region as compared with the *trans*-Golgi region. Current work is elucidating the consequences of ethanol-induced cholesterol depletion in the Golgi complex on Golgi function. An overriding conclusion of the work accomplished is that ethanol at concentrations observed in problem drinkers and alcoholics (e.g., an individual consuming either 6 beers, or 6 one shots of whiskey, or 6 glasses of wine) has a profound and multifaceted effect on cellular regulation of cholesterol.

14. SUBJECT TERMS
Alcoholism, Cardiovascular Disease, Cholesterol, Transport, Ethanol HDL, Human Aortic Smooth Muscle Cells, Human Endothelial Cells

15. NUMBER OF PAGES
58

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

INTRODUCTION

Risk of coronary heart disease (CHD) morbidity and mortality is reduced by moderate alcohol consumption whereas some studies suggest that heavy alcohol consumption has little or no benefit for CHD(1-4). A generally accepted finding of epidemiological and experimental studies is that high-density lipoproteins (HDL) levels are increased in association with alcohol consumption (3;5-7). An increase in HDL has been proposed to be one of the potential factors involved in the protective effects of moderate alcohol consumption on CHD (5;8). HDL levels however, are increased in heavy drinkers but their risk of CHD is higher than that of moderate alcohol drinkers (9-11). An important function of HDL is removal of excess lipids including cholesterol from cells and evidence has shown that chronic and acute administration of ethanol alters lipoprotein-mediated cholesterol efflux. Cholesterol efflux was decreased in mouse macrophages incubated with HDL of human alcoholic subjects (12). However, it was recently reported that cholesterol efflux was stimulated from Fu5AH rat hepatoma cells to plasma of human subjects who consumed 40 g of alcohol per day for 3 weeks (13). Acute administration of a very high ethanol concentration (350 mM) increased the rate of cholesterol efflux from erythrocytes to plasma (14). Ethanol concentrations (25 and 50 mM) that are seen in alcoholics and heavy drinkers inhibited cholesterol efflux from rat fibroblasts to HDL and apoA-I (15). Molecular mechanisms that are involved in effects of moderate and heavy alcohol consumption on cholesterol transport and cellular cholesterol distribution are not well-understood. We propose that ethanol modifies high density lipoprotein (HDL)-mediated cholesterol efflux from cells and low density lipoprotein (LDL)-mediated cholesterol influx into cells. These actions of ethanol alter the intracellular distribution of cholesterol leading to cellular dysfunction. Potential mechanisms that may explain effects of ethanol on cholesterol transport and distribution include ethanol perturbation of LDL and HDL trafficking, perturbation of the Golgi complex and signaling pathways such as phosphatidylcholine-phospholipase C (PC-PLC) and phosphatidylcholine-phospholipase D (PC-PLD) that are involved in reverse cholesterol transport. These potential mechanisms were studied in this grant that consisted of three major objectives: **Objective 1.** to determine effects of ethanol on LDL mediated cholesterol influx; **Objective 2.** to determine mechanisms of ethanol-induced alterations in the intracellular distribution of cholesterol; and **Objective 3.** to determine mechanisms of ethanol-induced perturbation of HDL-mediated cholesterol efflux from cells. Studies were conducted using a combination of fluorescence spectroscopy, confocal microscopy and cell culture techniques. Human aortic smooth muscle cells (HASMC) and human coronary artery endothelial cells (HCAEC) were used in the experiments.

BODY OF REPORT

In the initial review of our grant application, it was recommended that we include human aortic smooth muscle cells because those cells are the site of cholesterol accumulation in the atherosclerotic plaque. A revised Statement of Work to reflect addition of the cells was requested and this was submitted. This recommendation was very astute and human aortic smooth muscle cells (HASMC) were used in the project in addition to human coronary artery endothelial cells (HCAEC).

Ethanol Stimulates Uptake of LDL into HASMC and HCAEC. Effects of ethanol on the uptake of fluorescent labeled LDL were examined in HASMC and HCAEC using confocal microscopy and fluorescence spectroscopy, Cells were incubated with different concentrations of ethanol (0, 25, 50, and 75 mM) for 1, 2.5 and 5 h in the presence of fluorescent-labeled LDL in media that was lipoprotein-deficient. Figure 1 shows confocal images of HCAEC and HASMC incubated with different concentrations of ethanol for 5 h. The increase in the red intensity (BODIPY) and green intensity (DIL) intensity denotes an increase in the uptake of fluorescent-labeled LDL. Ethanol clearly stimulated uptake of LDL into HCAEC and HASMC (Figure 1).

Ethanol Stimulates LDL Uptake in HCAEC Using BODIPY-LDL

0 mM   25 mM   50 mM   75 mM

Ethanol Concentration

Ethanol Stimulates LDL Uptake in HASMC Using DIL-LDL

0 mM   25 mM   50 mM   75 mM

Ethanol Concentration

Figure 1.

Fluorescence intensity was quantified by measuring intensity in separate samples of HASMC and HCAEC incubated with fluorescent labeled LDL using a LS 50-B fluorimeter. Data in Figure 2 show that ethanol significantly ($p \leq 0.01$) increased the uptake of LDL into HASMC at each ethanol concentration at an incubation time of 5 h. Effects of ethanol were similar for each concentration. There was approximately a 36-38% increase in ethanol-induced LDL uptake.

Figure 2. Effects of ethanol on uptake of LDL in HASMC. Cells were incubated with DIL-LDL and different concentrations of ethanol for 5 h. Fluorescence intensity was determined using a fluorescence plate reader.Data are means $\pm$ S.E. *$p \leq 0.01$ as compared with 0 ethanol.

Figure 3. Effects of ethanol on uptake of LDL in HCAEC. Cells were incubated with BODIPY-LDL and different concentrations of ethanol for 5 h. Fluorescence intenswity was determined using a fluorescence plate reader. Data are means ± S.E. *p ≤ 0.001 as compared with 0 ethanol.

Ethanol had a greater effect on LDL uptake in HCAEC as compared with HASMC (Figure 3). There was a two-fold increase in LDL uptake when HCAEC were incubated with 25 mM ethanol.

Interestingly, effects of ethanol on LDL uptake were not concentration dependent. LDL uptake was similar at each ethanol concentration in HASMC and HCAEC (Figures 2 & 3). Uptake of LDL into cells may be particularly sensitive to effects of ethanol and significant uptake might be observed at ethanol concentrations lower than 25 mm. We tested ethanol concentrations of 7.5 mM, 10 mM and 15 mM. LDL uptake was not altered by lower ethanol concentrations (data not shown). Potential explanations for the stimulatory effects of ethanol on LDL uptake may reside in ethanol-induced inhibition of HMG-CoA reductase that could lead to upregulation of the LDL-receptor. Statins inhibit HMG-CoA reductase resulting in an increase in the number of LDL-receptors. Ethanol may also directly induce upregulation of the LDL-receptor.

Incorporation of Dehydroergosterol in HASMC. Ethanol significantly increased uptake of LDL. We next examined if ethanol would alter cholesterol efflux induced by HDL and apolipoprotein A-I (apoA-I) from cells. Dehydroergosterol (DHE) was used in the cholesterol efflux studies. DHE is a sterol occurring in yeast, it is very similar to cholesterol in its structure (Figure 4) and function, and it has been previously used as a cholesterol analogue in several different studies of sterol dynamics REVIEWED IN (16;17). DHE is an ideal cholesterol analogue because the sterol is naturally


Figure 4. Cholesterol and DHE Structure

fluorescent containing an endogenous fluorescent conjugated triene system in the B and C rings. DHE transport kinetics are analogous to those of cholesterol (17-19). We initially determined optimal conditions for DHE incorporation into HASMC. Three different concentrations of DHE (1,2,3 μg/ml of media) were incubated with HASMC for 18 h. Incorporation of DHE into cells was monitored by an increase in DHE fluorescence intensity. Figure 5 (Inset) shows that DHE concentration of 3 μg/ml

Figure 5. Incorporation of DHE into HASMC. In all experiments confluent cells were used. DHE (3μg/mL of media) was added to cells, and at each time point, cells were processed and DHE fluorescence measured. Data are means ± S.E. (n = 3) (Inset) HASMC were incubated with different concentrations of DHE for 18 h. Cells were then harvested and DHE fluorescence measured. Data are means ± S.E. (n = 3).

6

of media produced a robust increase in fluorescence intensity compared to the two lower concentrations. Fluorescence of non-incorporated DHE in the medium was negligible. The magnitude of fluorescence intensity was dependent also on the duration of incubation of DHE with cells. Fluorescence intensity of DHE steadily increased over time plateauing between 18 and 24 h of incubation (Figure 5).

Sterol Efflux to HDL and Effects of Ethanol. The purpose of these experiments was to determine if acute ethanol administration altered cholesterol efflux of HASMC induced by HDL. Confluent cells were preloaded with DHE (3 µg/ml of cell culture medium) for 18 h in 0.5% lipoprotein deficient serum. Cells were incubated for a period of 30 min with 0, 25, 50, or 75 mM ethanol after which 30 µg of HDL/ml of medium was added and cells were further incubated for 2 h. Cells were then washed twice with HBBS, trypsinized and neutralized with TNS or serum, collected, and centrifuged at 14,000 rpm for 1 min in an Eppendorf centrifuge (model

Figure 6. HDL-mediated DHE efflux from HASMC. Confluent cells were incubated with 3 µg of DHE/mL of cell culture medium for 18 h and then washed 2X with DHE-free medium and incubated with increasing concentrations of human HDL for 2 h. Cells were then harvested and DHE fluorescence measured. Data are means $\pm$ S.E. (n = 3). *p $\leq$ 0.02 as compared with no HDL.

541 7R). The pellet containing cells was washed twice with 1 ml PBS and homogenized in a loose-fitting homogenizer. The protein of the homogenized samples was determined by Bradford method. Sample (25µg protein) was placed in a quartz cuvette and DHE fluorescence intensity determined using a LS-50B fluorimeter (Perkin-Elmer, Norwalk, CT) with the excitation wavelength of 324 nm and emission wavelength of 376 nm.

Figure 6 shows the effects of increasing concentrations of HDL on sterol efflux from HASMC. DHE fluorescence was measured in cells following removal of HDL by centrifugation. HDL significantly (p $\leq$ 0.02) removed DHE from HASMC, and this effect was maximal at 30 µg of HDL protein/ml of medium and did not change significantly (30 versus 40 µg) when 40 µg of HDL protein/ml of medium was added (Figure 6).

There was approximately a 20% reduction in cholesterol in cells incubated with HDL alone compared with no HDL and ethanol significantly inhibited HDL-mediated cholesterol efflux from HASMC (Figure 7). Significant effects of ethanol were seen at


Figure 7. Ethanol Inhibits HDL-Mediated DHE Efflux from HASMC. Confluent cells were incubated with DHE as described in Fig. 2 and then incubated for 30 min with 0, 25, 50, or 75 mM ethanol after which 30 µg of HDL was added and cells incubated for 2 h after which time cells were harevested and DHE fluorescence measured. Control cells contained DHE but were not incubated with HDL or ethanol. Data are means $\pm$ S.E. (n = 4). *p $\leq$ 0.04 compared with HDL and 0 ethanol; **p $\leq$ 0.0001 compared with control.

7

ethanol concentrations of 50 and 75 mM ($p < 0.04$) but not at 25 mM ethanol (Figure 7). Effects of ethanol at 50 and 75 mM resulted in approximately 8-10% of cholesterol being removed from cells by HDL as compared to 20% removal by HDL alone.

Ethanol Inhibits Apolipoprotein A-I Mediated Cholesterol Efflux from HASMC and HCAEC. Cholesterol is removed from cells by HDL and lipid-free and lipid-poor apolipoproteins (20-22). Apolipoprotein A-I is the major apolipoprotein of HDL and we determined if ethanol would inhibit apoA-I induced cholesterol efflux. Incubation conditions were the same as described above except that cells were incubated with apoA-I and HCAEC were also used in addition to HASMC. There was a 24% reduction in sterol in HASMC when incubated with apoA-I alone as compared with cells not incubated with apoA-I and this difference was significant ($p \leq 0.0002$)

Figure 8. Ethanol Inhibits ApoA-I Mediated DHE Efflux from HASMC. Cells were incubated with DHE and incubated with ethanol as in Figures 2 and 7. After 30 min 30 µg of apoA-I was added and cells incubated for 2 h. Control cells contained DHE but were not incubated with apoA-I or ethanol. Data are means ± S.E. (n = 3). *$p \leq 0.001$ as compared with apoA-I 0 ethanol; ** $p \leq 0.0002$ as compared with control no apoA-I.

(Figure 8). Ethanol significantly ($p \leq 0.001$) inhibited apoA-I induced sterol efflux beginning at a concentration of 25 mM ethanol (Figure 8). In the presence of 50 and 75 mM ethanol, there was only approximately 6% and 3% of sterol removed respectively, by apoA-I.

Figure 9. Ethanol Inhibits ApoA-I Mediated Cholesterol Efflux from HCAEC. Treatment conditions were the same as described in Fig. 8. Data are means ± S.E. (n = 3). *$p \leq 0.005$ as compared with control no apoA-I and apoA-I no ethanol. **$p \leq 0.002$ as compared with apoA-I no ethanol.

There was a 36% reduction of sterol in HCAEC by apoA-I (Figure 9) as compared to control cells in the absence of apoA-I and this difference was significant ($p \leq 0.005$). Cholesterol efflux was significantly ($p \leq 0.005$) inhibited in the presence of 25 mM ethanol in contrast to apoA-I alone (Figure 9). Cholesterol efflux to apoA-I was abolished at ethanol concentrations of 50 and 75 mM (Figure 9). Cholesterol efflux induced by apoA-I was greater in HCAEC as compared with HASMC and inhibitory effects of ethanol on cholesterol efflux to HCAEC were also of greater magnitude.

Ethanol Reduces Cholesterol in the Golgi Complex of HASMC. We showed that ethanol inhibited cholesterol efflux from vascular cells to HDL and apoA-1 (Figures 7-9). The Golgi complex plays an important role in cholesterol trafficking and we proposed that ethanol may

8

Golgi complex. Initially, effects of ethanol on cholesterol levels in the Golgi complex were determined using fluorescent probes for cholesterol and the Golgi complex and confocal microscopy. HASMC were incubated with NBD-cholesterol that is a fluorescent-labeled sterol for 2.5 h. Cells were then incubated with BODIPY-ceramide that is a fluorescent marker for the Golgi complex. Figure 10, panels A, D, G, J and B, E, K, and H show fluorescence of NBD-cholesterol and BODIPY ceramide in HASMC, respectively. Panels C, F, I, and L show co-localization of the two fluorescent probes. Co-localization was reduced by ethanol treatment and percent changes in co-localization are shown in Figure 11. Significantly less co-localization occurred at 50 and 75 mM ethanol. There was a reduction in co-localization

Figure 11. Effects of Ethanol on Percent Co-Localization of NBD-Cholesterol and BODIPY TR Ceramide in HASMC. Cells were incubated with ethanol concentrations for 2 h. Percent co-localization was determined using MetaMorph software and data are means $\pm$ SEM (n=9). *p $\leq$ 0.02; *p$\leq$ 0.004 as compared with no ethanol.

Figure 10. Effects of Ethanol on Co-Localization of Probes for Cholesterol and Golgi

at 25 mM ethanol but this difference was not significantly different from the control cells. Changes in co-localization are indicative of a change in cholesterol levels. Ethanol reduced co-localization and this was interpreted as a reduction in cholesterol in the Golgi complex.

Cholesterol Distribution in the _Trans_ and _Cis_-Medial Regions of the Golgi Complex and Effects of Ethanol in HASMC. Data in Figures 10 and 11 were indicative of ethanol reducing cholesterol in the Golgi complex as revealed by confocal microscopy and the fluorescent cholesterol analogue, NBD-cholesterol and a fluorescent marker for the Golgi complex, BODIPY TR ceramide. The Golgi complex consists of different regions and it has been reported that there is an increasing gradient of cholesterol from the _cis_ region to the _trans_ region of the Golgi complex. We have applied a method in our lab to isolate different Golgi regions using sucrose density centrifugation. Our initial studies were to establish the methodology in our lab with an immortalized astrocyte cell line because those cells are provided to our lab at little or no costs as compared with the relatively expensive HASMC (_23_). HASMC were harvested and washed twice with PBS. The cells were suspended in G-buffer (10 mM Tris-HCl, 0.25 M Sucrose and 2 mM $MgCl_2$, pH 7.4) containing 10 mM $CaCl_2$. Leupeptin and PMSF were added

to the cell suspension to inhibit proteolytic enzymes, prior to homogenization. The cells were homogenized in a Potter-type homogenizer and homogenized with 20-30 strokes using a serrated homogenizing pestle. The homogenate was centrifuged at 5,000 x g for 10 min. The pellet was suspended and homogenized in 1.4 M sucrose and over layered with 0.8 M, 1.0 M, 1.2 M sucrose gradients in ultracentrifuge tubes. Samples were then centrifuged at 95,000 x g for 2.5 h in a SW28 rotor in a Beckman L8-70 ultracentrifuge. Each interface was carefully removed and diluted with G buffer and centrifuged in a SS34 rotor at 45,900 x g for 20 min. Each pellet was suspended in buffer and used for the experiments. Protein concentrations of the fractions were determined using Bradford assay. Cholesterol content in each fraction was determined enzymatically in a microassay using the Boehringer-Mannheim diagnostic kit.

Figure 12. Effects of Ethanol on Cholesterol Distribution in the *Trans*- and *Cis*-Medial Regions of the Golgi Complex of HASMC. Cells were incubated with different concentrations of ethanol for 2 h. Golgi complex regions were isolated using sucrose density centrifugation. Data are means ± S.E. (n = 3). +p ≤ 0.01 as compared with the *trans*-region no ethanol; *p ≤ 0.02 as compared with all ethanol concentrations.

Figure 12 shows that the two fractions thought to represent the *trans* Golgi and the *cis*-medial region contained different levels of cholesterol. Cholesterol abundance was significantly higher in the *trans*-Golgi region compared with the *cis*-medial Golgi region. These results are similar to other cell types in which cholesterol levels were higher in the *trans*-Golgi as compared with the *cis*-medial region 1410,1390}. The *trans* Golgi region contained 58% of the total Golgi cholesterol. Ethanol significantly reduced cholesterol in both Golgi regions but the *cis*-medial region region was more affected by ethanol, particularly at 25 mM ethanol than the *trans*-Golgi region. Cholesterol levels of the *cis*-medial region were reduced by 59% when incubated with 25 mM ethanol as compared with 29% in the *trans*-region. Effects of ethanol at 50 mM and 75 mM were similar for both the *trans*-region and the *cis*-medial region. Effects of ethanol on Golgi cholesterol levels cannot be explained by differences in cholesterol synthesis or degradation because cholesterol levels in the cell homogenate fractions did not differ (data not shown). Ethanol appears to induce movement of cholesterol from the Golgi complex. The destination of the cholesterol removed from the Golgi complex may be to the cell membrane or intracellular organelles such as the endoplasmic reticulum and we are currently examining those potential sites. Ethanol at 25 mM had a substantially greater effect on reducing cholesterol in the *cis*-medial region than the *trans*-Golgi region. These differences may be associated with ethanol's ability to have a greater perturbing effect on membranes with lower amounts of cholesterol (*24;25*). It would be expected that more ethanol partitions into the *cis*-medial region as compared with the *trans*-Golgi region and stimulates cholesterol removal by vesicular or non-vesicular mechanisms. We are currently examining potential mechanism of cholesterol removal

from the Golgi complex. Optimal cholesterol levels are necessary for Golgi function (*26*) and the ethanol-induced reduction of Golgi cholesterol suggests that cholesterol-dependent Golgi functions showed be altered.

Ethanol Stimulates PC-PLC and PC-PLD in HASMC. Ethanol stimulated movement of cholesterol out of the Golgi complex thus argues against the idea that ethanol may inhibit trafficking of cholesterol from the Golgi complex, and inhibition of cholesterol efflux mediated by HDL and apoA-I. Another potential mechanism for ethanol-induced inhibition of cholesterol efflux may involve the actions of two phospholipases, phosphatidylcholine-phospholipase C (PC-PLC) and phosphatidylcholine-phospholipase D (PC-PLD). HDL and apoA-I are thought to stimulate a G-protein coupled receptor that induces hydrolysis of PC by PC-PLC and PLD. Stimulation of these pathways increases cholesterol efflux (*27;28*). It has been proposed that phosphatidic acid that is a metabolite of PC hydrolysis by PC-PLD may be involved in regulation of cholesterol efflux (*27*). PC-PLD is of particular importance with respect to action of ethanol because in the presence of alcohols there is a transphosphatidylation reaction and a phosphatidylalcohol is formed and a reduction of PA production (*29;30*). PA has been shown to stimulate cholesterol efflux (*27*). Ethanol may alter activity of PC-PLC and PC-PLD that could impact on cholesterol efflux. Effects of ethanol on activation of PC-PLC and PC-PLD activity were determined in HASMC using an enzyme coupled assay and *N*-acetyl-3,7-dihydroxyyphenoxazine using the Amplex red PC-PLC and PC-PLD assay kits (Molecular Probes, Eugene, OR)(*31*). Cells were incubated with ethanol (0, 25, 50, and 75 mM) for 2 h after

Figure 13. Ethanol Stimulates PC-PLD Activity in HASMC. Cells were incubated with different concentrations of ethanol for 2 h after which cells were harvested and PC-PLD activity determined by an enzyme coupled assay. Data are means ± S.E. (n = 4). *p ≤ 0.004 as compared with no ethanol; **p ≤ 0.0001 as compared with each treatment condition.

Figure 14. Effects of Ethanol on PC-PLC Activity in HASMC. Cells were incubated with different ethanol concentrations for 2 h after which time cells were harvested and PC-PLC activity determined using an enzyme coupled assay. Data are means ± S.E. (n = 4). *p ≤ 0.02 as compared with each treatment condition.

which time cells were then washed twice with HBBS, trypsinized and neutralized with TNS or serum, collected, and centrifuged at 14,000 rpm for 1 min in an Eppendorf centrifuge (model 541 7R). The pellet containing cells was washed twice with 1 ml PBS and homogenized in a loose-fitting homogenizer and aliquots placed in 96 well-plates and the assay reagents added. The intensity of the Amplex Red complex formed was measured after 60 min in a fluorescence microplate reader (Spectra Max Gemini XS, Molecular Device, Sunnyvale, CA) using an excitation wavelength of 542 nm and an emission wavelength of 590 nm. PC-PLD was significantly stimulated by ethanol (Figure 13). There was a 2-fold increase in PC-PLD activity by 25 mM ethanol as compared to control cells (p≤ 0.0001). It can be seen in Figure 13 that both

11

50 and 75 mM ethanol significantly (p ≤ 0.004) increased PC-PLD activity as compared to control cells but this effect was certainly not as large as observed for 25 mM ethanol. Activity of PC-PLC was significantly (p ≤ 0.02) increased by 25 mM ethanol as compared to the control cells resulting in a 16% increase in activity of the enzyme (Figure 14). PC-PLC activity was higher in the presence of 50 or 75 mM ethanol as compared to control but these differences were not significant. The increase in activities of PC-PLD and PC-PLC by ethanol is in agreement with earlier reports in studies of hepatocytes and fibroblasts (32;33). Activity of both phospholipases was stimulated more by 25 mM ethanol than 50 or 75 mM ethanol. This stimulation was most noticeable for PC-PLD activity. This concentration dependent effect of ethanol could be due to inhibition of upstream effectors of PC-PLD and PC-PLC such as protein kinase C, G-protein-coupled receptors, and apoA-I at the higher ethanol concentrations (34).

Figure 15. Effects of Propranolol on ApoA-I Mediated Cholesterol Efflux from HASMC. Treatment conditions were the same as described in Fig. 8 except cells were incubated with or without 100 μM for 2 h. Data are means ± S.E. (n = 3). *p ≤ 0.01 as compared to to control no apoA-I.

Effects of Propranolol on ApoA-I induced Cholesterol Efflux from HASMC. PC-PLD is of particular importance with respect to action of ethanol because in the presence of alcohols there is a transphosphatidylation reaction and a phosphatidylalcohol is formed and a reduction of PA production (29;30). PA has been shown to stimulate cholesterol efflux (27). Propranolol blocks PA phosphohydrolase resulting in an increase in PA. Therefor, we determined if propranolol would stimulate cholesterol efflux to apoA-I and if ethanol would interfere with this process in HASMC. Figure 15 shows that propranolol stimulated cholesterol efflux from HASMC to apoA-I as compared with apoA-I alone. It was predicted that ethanol may inhibit effects of propranolol on cholesterol efflux due to a reduction in PA formation. It can be seen that ethanol significantly inhibited the stimulatory effects of propranolol on cholesterol efflux.

KEY RESEARCH ACCOMPLISHMENTS

• Ethanol markedly alters cholesterol trafficking into and out of vascular cells at concentrations observed in heavy drinkers and alcoholics.

• Ethanol stimulates uptake of low density lipoproteins (LDL) into human aortic smooth muscle cells (HASMC) and human coronary artery endothelial cells (HCAEC).

• Ethanol inhibits cholesterol efflux induced by high density lipoproteins (HDL) and apolipoprotein A-I (apoA-I) in HASMC and HCAEC.

• Ethanol had a greater effect on cholesterol efflux of HCAEC than HASMC.

• ApoA-I mediated cholesterol efflux was more inhibited by ethanol than was HDL-mediated cholesterol efflux.

12

KEY RESEARCH ACCOMPLISHMENTS (Continued)

•   The Golgi complex plays an important role in cholesterol trafficking both within cells and trafficking out cell and this organelle is a target of ethanol.

•   Ethanol reduced cholesterol levels in the Golgi complex of cells as revealed by confocal microscopy.

•   The *trans*-Golgi region contains more cholesterol than the *cis*-medial region in HASMC. Ethanol had a larger effect on removing cholesterol from the *cis*-medial region as compared with the *trans*-Golgi region. This difference in effects of ethanol on Golgi complex regions may be due to the ability of ethanol to partition into those regions.

•   Ethanol effects on the Golgi complex may not explain ethanol-induced inhibition of HDL and apoA-I mediated cholesterol efflux. Instead, ethanol depletion of Golgi cholesterol may impair cholesterol-dependent Golgi functions.

•   PC-PLD is associated with cholesterol efflux and ethanol stimulated activity of this enzyme. Ethanol-induced inhibition of cholesterol efflux may involve PC-PLD function as a result of ethanol reducing phosphatidic acid and increasing levels of phosphatidylethanol.

REPORTABLE OUTCOMES

Wood, W.G., Avdulov, N.A., Chochina, S.V., and Igbavboa, U. Lipid carrier proteins and ethanol. *Journal of Biomedical Science*, 2001, 8, 114-118.

Igbavboa, U., Kiss, Z., and Wood, W. G. Cholesterol in Golgi complex is modified by ethanol as revealed by confocal microscopy. *FASEB Journal*, 2001, *15*, A529.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Johnson, L.N.A., Wood, W.G. HDL and apolipoprotein A-I induced cholesterol efflux is inhibited by ethanol in human smooth muscle aortic cells: Roles of phospholipases C and D. *Alcoholism: Clinical and Experimental Research,* 2002, *26*, 60A.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Studniski, A.E., Johnson, L.N.A., Wood, W.G. HDL and apolipoprotein A-I induced cholesterol efflux is inhibited by ethanol in human smooth muscle aortic cells: Roles of phospholipases D and the Golgi complex. *Alcohol and Alcoholism*, 38, 474, 2003.

Igbavboa, U., Pidcock, J.M., Jognson, L.N.A., Malo, T.M., Sun, G.Y., and Wood, W.G. Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and amyloid β-peptide$_{1-42}$. *Journal of Biological Chemistry*, 278, 17150-17157, 2003.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Johnson, L.N.A., Wood, W.G. Cholesterol efflux is inhibited by ethanol in human aortic smooth muscle cells: Differences in sensitivity of HDL and apolipoprotein A-I and the roles of phosphatidylcholine-phospholipase C and D. *Biochemistry*, 2004, submitted.

Igbavboa, U., Johnson, L.N.A., and Wood, W.G. Ethanol perturbation of the Golgi complex in human aortic smooth muscle cells. manuscript in preparation.

CONCLUSIONS

Cholesterol is important in regulation of cell structure and function. Equally important is the role that cholesterol plays in vascular disease. The focus of this grant was on mechanisms of alcohol induced disruption of cellular cholesterol transport and distribution (Figure 16). An overriding conclusion of our work is that ethanol at concentrations observed in problem drinkers and alcoholics (e.g., an individual consuming either 6 beers, or 6 one shots of whiskey, or 6 glasses of wine) has a profound and multifaceted effect on cellular regulation of cholesterol. Our work to date shows that many of the systems involved in regulating cholesterol transport are perturbed by ethanol (HDL, apoA-I, LDL, Golgi complex, PC-PLC, PC-PLD, phosphatidic acid). Alcohol results in more cholesterol being taken into cells and less cholesterol being removed from cells. These findings have several important implications. The clinical determination of cholesterol is based on amount of cholesterol in the serum (total cholesterol, LDL-cholesterol, HDL-cholesterol) but not the amount of cholesterol in cells. Cholesterol content in cells of problem drinkers and alcoholics may be elevated as compared to control subjects and such a difference would not be detected by routine clinical assays for cholesterol. Optimal cholesterol levels are essential for the normal function of cells. Alcohol-induced changes in cell cholesterol, particularly the Golgi complex could have profound pathophysiological consequences on cell function. The Golgi complex plays an important role in protein and lipid trafficking and our findings demonstrate that ethanol reduces cholesterol in the Golgi complex. Future studies will elucidate mechanisms of ethanol-induced reduction of cholesterol in the Golgi complex and the consequences of such reduction on Golgi complex function.

Figure 16. Ethanol and Cholesterol Trafficking in Vascular Cells

REFERENCES

1. Eagles, C. J. and Martin, U. (1998) *J. Clin. Pharm. Ther. 23*, 1-9.

2. Klatsky, A. L. (1999) *Alcohol Res. Health 23*, 15-23.

3. Rimm, E. B., Williams, P., Fosher, K., Criqui, H., and Stampfer, M. J. (1999) *Br. Med. J. 319*, 1523-1528.

4. Sesso, H. D. and Gaziano, J. M. (1999) *Curr. Opin. Nephrol. Hypertens 8*, 353-357.

5. Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., and Zukel, W. J. (1977) *Lancet ii*, 153-155.

6. Klatsky, A. L. (1994) *Alcohol Clin. Exp. Res. 18*, 88-96.

7. Srivastava, L. M., Vasisht, S., Agarwal, D. P., and Goedde, H. W. (1994) *Alc. & Alcohol. 29*, 11-24.

8. Criqui, M. H., Cowan, L. D., Tyroler, H. A., Bangdiwala, S., Heiss, G., and Wallace, R. B. (1987) *Am. J. Epidemiol. 126*, 629-637.

9. Frohlich, J. J. (1996) *Clinica Chimica Acta 246*, 39-49.

10. Goldberg, D. M., Hahn, S. E., and Parkes, J. G. (1995) *Clinica Chimica Acta 237*, 155-187.

11. Hojnacki, J. L. (1994) *Nutrition Research 14*, 1241-1295.

12. Rao, M. N., Liu, Q.-H., Seef, L. B., Strader, D. B., Marmillot, P. R., and Lakshman, M. R. (2000) *Metabolism 49*, 1406-1410.

13. van der Gaag, M. S., van Tol, A., Vermunt, S. H. F., Scheek, L. M., Schaafsma, G., and Hendriks, H. F. J. (2001) *J. Lipid Res. 42*, 2077-2083.

14. Daniels, C. K. and Goldstein, D. B. (1982) *Mol. Pharmacol. 21*, 694-700.

15. Avdulov, N. A., Chochina, S. V., Igbavboa, U., and Wood, W. G. (2000) *Biochemistry 39*, 10599-10606.

16. Schroeder, F., Frolov, A. A., Murphy, E. J., Atshaves, B. P., Pu, L., Wood, W. G., Foxworth, W. B., and Kier, A. B. (1996) *Proc. Soc. Exp. Biol. Med. 213*, 150-177.

17. Mukherjee, S., Zha, X., Tabas, I., and Maxfield, F. R. (1998) *Biophys J 75*, 1915-1925.

18. Kier, A. B., Sweet, W. D., Cowlen, M. S., and Schroeder, F. (1986) *Biochim Biophys Acta 861*, 287-301.

19. Nemecz, G., Fontaine, R. N., and Schroeder, F. (1988) *Biochim Biophys Acta 943*, 511-521.

20. Rothblat, G. H., de la Llera-Moya, M., Atger, V., Kellner-Weibel, G., Williams, D. L., and Phillips, M. C. (1999) *J. Lipid Res. 40*, 781-796.

21. Mendez, A. J. (1997) *J. Lipid Res. 38*, 1807-1821.

22. Zhao, Y., Sparks, D. L., and Marcel, Y. L. (1996) *J. Biol. Chem. 271*, 25145-25151.

23. Igbavboa, U., Pidcock, J. M., Johnson, L. N. A., Malo, T. M., Studniski, A., Sun, G. Y., and Wood, W. G. (2003) *J. Biol. Chem. 278*, 17150-17157.

24. Chin, J. H. and Goldstein, D. B. (1984) *Lipids 19*, 929.

25. Wood, W. G., Gorka, C., and Schroeder, F. (1989) *J. Neurochem 52*, 1925-1930.

26. Wang, Y., Thiele, C., and Huttner, W. B. (2000) *Traffic 1*, 952-962.

27. Walter, M., Reinecke, H., Gerdes, U., Nofer, J.-R., Höbbel, G., Seedorf, U., and Assman, G. (1996) *J. Clin. Invest. 98*, 2315-2323.

28. Murthy, K. S. and Makhlouf, G. M. (1995) *Mol. Pharmacol. 48*, 293-304.

29. Heller, M. (1978) *Adv. Lipid Res. 16*, 267-326.

30. Moehren, G., Gustavsson, L., and Hoek, J. B. (1994) *J. Biol. Chem. 269*, 838-848.

31. Zhou, M., Diwu, Z., Panchuk-Voloshina, N., and Haugland, R. P. (1997) *Anal Biochem 253*, 162-168.

32. Kiss, Z. and Anderson, W. B. (1990) *J. Biol. Chem. 265*, 7345-7350.

33. Pittner, R. A. and Fain, J. N. (1992) *Biochim Biophys Acta 1133*, 316-320.

34. Haidar, B., Mott, S., Boucher, B., Lee, C. Y., Marcil, M., and Genest, Jr. J. (2001) *J. Lipid Res. 42*, 249-257.

BIBLIOGRAPHY OF PUBLICATIONS AND MEETING ABSTRACTS

Wood, W.G., Avdulov, N.A., Chochina, S.V., and Igbavboa, U. Lipid carrier proteins and ethanol. *Journal of Biomedical Science*, 2001, 8, 114-118.

Igbavboa, U., Kiss, Z., and Wood, W. G. Cholesterol in Golgi complex is modified by ethanol as revealed by confocal microscopy. *FASEB Journal*, 2001, *15*, A529.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Johnson, L.N.A., Wood, W.G. HDL and apolipoprotein A-I induced cholesterol efflux is inhibited by ethanol in human smooth muscle aortic cells: Roles of phospholipases C and D. *Alcoholism: Clinical and Experimental Research,* 2002, *26*, 60A.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Studniski, A.E., Johnson, L.N.A., Wood, W.G. HDL and apolipoprotein A-I induced cholesterol efflux is inhibited by ethanol in human smooth muscle aortic cells: Roles of phospholipases D and the Golgi complex. *Alcohol and Alcoholism*, 38, 474, 2003.

Igbavboa, U., Pidcock, J.M., Jognson, L.N.A., Malo, T.M., Sun, G.Y., and Wood, W.G. Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and amyloid β-peptide$_{1-42}$. *Journal of Biological Chemistry*, 278, 17150-17157, 2003.

Igbavboa, U., Pidcock, J.M., Malo, T.M., Studniski, A.E., Johnson, L.N.A., and Wood, W.G. High density lipoprotein and apolipoprotein A-I-induced cholesterol efflux is inhibited by ethanol in human smooth muscle aortic cells: Roles of lipoprotein structure and the Golgi complex. PRMRP Military Health Research Forum, San Juan, Puerto Rico, April 25-28, 2004

Igbavboa, U., Pidcock, J.M., Malo, T.M., Johnson, L.N.A., and Wood, W.G. Cholesterol efflux is inhibited by ethanol in human aortic smooth muscle cells: Differences in sensitivity of HDL and apolipoprotein A-I and the roles of phosphatidylcholine-phospholipase C and D. *Biochemistry*, 2004, submitted.

Igbavboa, U., Johnson, L.N.A., and Wood, W.G. Ethanol perturbation of the Golgi complex in human aortic smooth muscle cells. manuscript in preparation.

PERSONNEL ON THE PROJECT

W. Gibson Wood, Ph.D.	Principal Investigator
Urule Igbavboa, D.Sc.	Research Associate
Justine Pidcock, B.S.	Technician
Todd M. Malo, B.S.	Technician
Ann M. Studniski, B.S.	Technician
Leslie N. A. Johnson, B.S.	Technician

Lipid Carrier Proteins and Ethanol

W. Gibson Wood   Nicolai A. Avdulov   Svetlana V. Chochina   Urule Igbavboa

Geriatric Research, Education and Clinical Center, VA Medical Center, and Department of Pharmacology,
University of Minnesota School of Medicine, Minneapolis, Minn., USA

Key Words

Alcoholism · Apolipoproteins · Cardiovascular disease · Cholesterol · Ethanol · High-density lipoproteins · Lipids · Low-density lipoproteins · Reverse cholesterol transport

Abstract

Ethanol has a pronounced effect on lipid homeostasis. It is our overall hypothesis that certain lipid carrier proteins are targets of acute and chronic ethanol exposure and that perturbation of these proteins induces lipid dysfunction leading to cellular pathophysiology. These proteins include both intracellular proteins and lipoproteins. This paper examines recent data on the interaction of ethanol with these proteins. In addition, new data are presented on the stimulatory effects of ethanol on low-density-lipoprotein (LDL)-mediated cholesterol uptake into fibroblasts and direct perturbation of the LDL apolipoprotein, apolipoprotein B. A cell model is presented that outlines potential mechanisms thought to be involved in ethanol perturbation of cholesterol transport and distribution.

Copyright © 2001 National Science Council, ROC and S. Karger AG, Basel

Lipid homeostasis is altered by chronic ethanol consumption. Ethanol-induced changes in lipid homeostasis have been reported in alcoholics, heavy drinkers and animal models of alcoholism [16, 23, 25, 29, 32]. Examples of ethanol-induced changes in lipid homeostasis are accumulation of triacylglycerols and other lipids in the liver, alterations in cholesterol transport, membrane cholesterol asymmetry, lipoprotein distribution and the polyphos-

phoinositide cascade. There is increasing evidence that certain lipid carrier or transport proteins including lipoproteins are targets of ethanol [2, 5, 13, 19, 22]. We have been studying the dynamic interaction of ethanol with some of the lipid carrier proteins, and those data are summarized in table 1. Liver fatty-acid-binding protein (L-FABP) is a lipid carrier protein that binds cholesterol, fatty acids, fatty acylcoenzyme A, retinol, heme, hematin, lysophospholipids, bilirubin, prostaglandins and other amphipathic ligands [20]. This protein is found in the liver and other organs. Expression of L-FABP was significantly increased in livers of mice maintained on an ethanol liquid diet for 8 weeks as compared with livers of pair-fed control mice [5]. There was a 43% increase in the amount of L-FABP in livers of the chronic ethanol-treated mice. An earlier study had also found that L-FABP was

Table 1. Lipid carrier proteins and ethanol

Protein	Ethanol dynamics			Ref.
	in vivo	sterol transport	lipid binding	
L-FABP	↑ Liver		No effect C, SA	5, 27
SCP-2	↑ Brain		↓ C, PC, SA	19, 3
Apo A-I			↓ PC, no effect C	4
ApoA-I-PC		↓ Efflux	↓ C	4
HDL		↓ Efflux	No effect C	4
BSA			↓ C, PC, PA	2

C = Cholesterol; PC = phosphatidylcholine; PA = parinaric acid; SA = stearic acid.

increased in livers of chronic ethanol-treated rats [21]. The increase in L-FABP expression in chronic ethanol-treated animals could be due to ethanol interfering with the binding capacity of L-FABP for its lipid ligands. This potential effect of ethanol on L-FABP was examined using fluorescent-dye-labeled cholesterol and stearic acid. We did not observe any effect of ethanol on cholesterol or stearic acid binding to L-FABP [27]. Chronic ethanol consumption could induce a posttranslational modification of L-FABP that could interfere with lipid binding. In our binding studies, we used rat liver recombinant L-FABP and not L-FABP from livers of chronic ethanol-treated animals. It was reported that the affinity for palmitate was greatly reduced in a delipidated cytosolic liver homogenate of chronic ethanol-treated rats [21]. In the same study, L-FABP amounts increased in the chronic ethanol-treated rats.

Sterol carrier protein 2 (SCP-2) is an intracellular protein that is found in peroxisomes and binds cholesterol, phospholipids and fatty acids [26]. This protein is found in the liver, brain and other organs. The only difference between the liver form of SCP-2 and brain SCP-2 is a single amino acid resulting in a conservative replacement of Ala[55] for Val[55] [19]. SCP-2 expression in liver was not affected by chronic ethanol consumption [5]. However, SCP-2 expression was increased in brain tissue of chronic ethanol-treated mice [19]. There was a 56% increase in SCP-2 in synaptosomes of chronic ethanol-treated mice as compared with the pair-fed control mice. In contrast to L-FABP, ethanol inhibited binding of lipids to SCP-2 with cholesterol binding being most affected [3]. The association constants (K_a) of the lipid ligand-SCP-2 complex were in the following order: NBD cholesterol > NBD phosphatidylcholine (PC) > NBD stearic acid. Ethanol, beginning at a concentration of 25 mM, significantly reduced the affinity of NBD cholesterol and NBD PC for SCP-2. Effects of ethanol on the K_a of NBD stearic acid were significant only at the highest concentration that was examined (200 mM).

The physiological function of SCP-2 has not been elucidated [6, 26]. SCP-2 may be involved in the intracellular trafficking of cholesterol [26]. SCP-2 decreases the half-life of sterol exchange between plasma membranes. SCP-2 is a peroxisomal protein, and transfer of cholesterol to the plasma membrane was found to be dependent on the amount of SCP-2 in peroxisomes [6]. Concomitant with ethanol-induced changes in SCP-2 expression in the brain was the finding that the transbilayer distribution of cholesterol was modified in synaptic plasma membranes of chronic ethanol-treated mice [31]. The amount of choles-

terol in the exofacial leaflet was doubled in chronic ethanol-treated mice as compared with control mice. Total cholesterol amounts in synaptic plasma membranes did not differ between the ethanol and control groups. Mechanisms involved in regulating the transbilayer distribution of cholesterol are poorly understood. SCP-2 may be incorporated into the membrane and transports cholesterol from the cytofacial to the exofacial leaflet. Binding of SCP-2 to plasma membranes has been reported [33]. The increased expression of SCP-2 in brains of chronic ethanol-treated mice may be in response to ethanol interfering with binding of ligands to the protein. SCP-2, an intracellular protein, may then be taken up into the cytofacial leaflet that contains approximately 85% of the total synaptic plasma membrane cholesterol and this membrane-bound SCP-2 then translocates cholesterol to the exofacial leaflet. A recent report found that SCP-2 expression inhibited cholesterol efflux from L cell fibroblasts [1].

Cholesterol efflux from cells is an important function whereby cholesterol is removed from cells and transported to the liver. High-density lipoprotein (HDL), lipid-free and lipid-poor apolipoproteins act as acceptors for cholesterol efflux [7, 9, 18, 24, 35]. There has been substantial interest in the relationship between HDL levels and ethanol consumption. A generally accepted finding of both epidemiological and experimental studies is that HDL levels are increased in association with alcohol consumption [8, 11, 12, 14, 15, 23, 28]. Moreover, this lipoprotein and its subfractions are thought to play an important role in the reduced risk of coronary heart disease in moderate alcohol drinkers. What would appear to be an apparent contradiction is that HDL levels have been shown to be elevated in alcoholics but several studies report that the incidence of coronary heart disease is higher in alcoholics even when factors such as cigarette smoking and other factors are taken into consideration [11, 12, 14]. Recent data from our laboratory and another laboratory may contribute to an understanding of this apparent contradiction. We have recently reported that ethanol at concentrations commonly observed during periods of heavy drinking (25 and 50 mM) significantly inhibited cholesterol efflux from fibroblasts to HDL and to apolipoprotein A-I (apoA-I)-PC complexes [4]. While ethanol reduced cholesterol efflux to both HDL and apoA-I-PC, the mechanism of action was different. Ethanol inhibited incorporation of cholesterol into apoA-I-PC but did not affect incorporation of cholesterol into HDL. Cholesterol efflux mediated by HDL may result from direct contact of HDL with the cell exofacial leaflet of the plasma membrane, and ethanol may interfere with this contact. ApoA-

Fig. 1. Effects of ethanol on LDL-mediated cholesterol influx. The fluorescent cholesterol analogue dehydroergosterol (DHE) was incorporated into human plasma LDL. CREF fibroblasts were then incubated with LDL in the presence or absence of 25 and 50 mM ethanol for 5 h after which time cells were centrifuged and the fluorescence intensity of dehydroergosterol was measured. Data are means ± SEM of dehydroergosterol in fibroblasts (n = 4 experiments). *p ≤ 0.005 as compared to LDL control.

Fig. 2. Ethanol and tryptophan fluorescence polarization of apoB. Steady-state polarization was measured using tryptophan residues of apoB excited at 286 nm and emission at 335 nm in the presence and absence of 50 and 100 mM ethanol at 37 °C. Data are means ± SEM of polarization values for apoB tryptophan residues (n = 5 experiments). *p ≤ 0.001 as compared to 0 ethanol.

I-PC may incorporate cholesterol by the combined effects of membrane contact and aqueous diffusion. Lakshman's laboratory [22] has shown that HDL of alcoholic patients was less effective in removing cholesterol from mouse macrophages than HDL of control subjects. The uptake of HDL by HepG2 cells was significantly reduced in HDL samples of alcoholic patients. It should be noted that ethanol was not added in that study. A very important conclusion derived from the two studies is that the process whereby cells remove cholesterol is impaired by concentrations of ethanol routinely observed in heavy drinkers and by changes in HDL structure induced by chronic ethanol consumption.

Cholesterol influx mediated by low-density lipoprotein (LDL) is affected by ethanol and is opposite to effects observed for HDL on cholesterol efflux. It can be seen in figure 1 that ethanol significantly increased the uptake of LDL labeled with the fluorescent sterol dehydroergosterol into fibroblasts. There was approximately a 25% increase in fluorescence intensity of fibroblasts incubated with LDL and 25 mM ethanol, and 50 mM ethanol had even a larger effect on LDL-mediated sterol uptake (fig. 1). Potential mechanisms may include structural changes in apoB, the main apolipoprotein of LDL, providing a more energy-efficient conformation state or changes in the lipid environment associated with the LDL receptor or direct effects on the LDL receptor. We did observe that ethanol decreased fluorescence polarization of tryptophan residues of apoB (fig. 2). On the other hand, fluorescence polarization of tryptophan residues of apoA-I was increased by ethanol [4]. The restricted motion of apoA-I tryptophan residues induced by ethanol may interfere with lipid binding to the apolipoprotein.

Cholesterol transport into and out of cells is altered by ethanol concentrations that routinely occur in heavy drinkers (fig. 3). Ethanol stimulates the uptake of cholesterol into cells and inhibits cholesterol efflux from cells. Several potential mechanisms (LDL receptor binding and expression, LDL protein and lipid domains, selective uptake by coated pits) may explain this increase. Once cholesterol is internalized, it is delivered to lysosomes where the apolipoprotein component of LDL is degraded to amino acids, cholesterol esters are hydrolyzed by acid lipase and cholesterol is transported to different structures. Ethanol could modify the intracellular distribution of cholesterol by affecting the transport to different structures. Ethanol may directly act on HDL or lipid-poor apoA-I and alter protein conformation. Ethanol may perturb the membrane lipid environment that could affect cholesterol efflux. Ethanol could act on acylcoenzyme A cholesterol acyltransferase resulting in changes in the ratio of esterified cholesterol to free cholesterol and such changes affecting reverse cholesterol transport. Ethanol could perturb the Golgi apparatus that has been proposed to be an important component in both transport of cholesterol to the plasma membrane as well as transport from

Fig. 3. Potential mechanisms of ethanol effects on cellular cholesterol transport and distribution. Ethanol increases LDL cholesterol uptake by directly altering apolipoprotein structure and possibly the receptor (LDLR). Internalized cholesterol may be processed through an endosome-lysosome pathway and transported to the endoplasmic reticulum (ER) and Golgi apparatus. Ethanol may increase the activity of acylcoenzyme A cholesterol acyltransferase (ACAT) resulting in an increase in esterified cholesterol that would not be available for transport. Transport of cholesterol to the plasma membrane may be inhibited by ethanol acting on caveolin, rafts or SCP-2. Additional mechanisms may include perturbation and structural changes of HDL, pre-β-HDL, caveolae and the scavenger receptor class B type 1 (SR-BI) receptor. The net result of ethanol-induced changes in cellular cholesterol homeostasis may include dysfunction of membrane proteins, the signal transduction pathway leading to apoptosis. ce = Cholesterol ester; fc, FC = free cholesterol; GP-I = glycosylphosphatidyl inositol; LRP = lipoprotein receptor-related protein; sm, SM = sphingomyelin.

the plasma membrane to the Golgi apparatus and other intracellular compartments [9, 17, 24]. Both monensin and brefeldin A inhibited cholesterol efflux to HDL from fibroblasts by acting on the trans-cisternae of the Golgi apparatus and cis- and medial Golgi cisternae, respectively [17]. Agents that disrupt the Golgi apparatus alter the intracellular cholesterol distribution to the plasma membrane and other structures [10]. Chronic ethanol consumption has been shown to alter cholesterol domains in brain plasma membranes, but there are little if any data on intracellular domains and ethanol in any cells [30, 31].

Marked changes in cholesterol distribution can occur in the absence of changes in the total amount of cellular cholesterol that could in turn affect cell function. Lipid transport involving caveolin, vesicles and SCP-2 to the plasma membrane could be altered by ethanol.

One conclusion is that cells of individuals who consume at least 5–6 drinks contain more cholesterol as compared to moderate drinkers. Therefore, cholesterol homeostasis of heavy drinkers is impacted by the acute and chronic effects of ethanol. It is well established that cholesterol plays an important role in cell structure and func-

tion. Membrane fluidity and activity of Na⁺-K⁺-ATPase are regulated by cholesterol. Apoptosis was induced by loading macrophages with cholesterol, and this lethal effect of cholesterol was thought to be due to activation of the Fas pathway [34]. Acute and chronic effects of ethanol on cellular cholesterol homeostasis could certainly contribute to pathophysiology occurring in alcoholics.

References

1 Atshaves BP, Starodub O, McIntosh A, Petrescu A, Roths JB, Kier AB, Schroeder F. Sterol carrier protein-2 alters HDL-mediated cholesterol efflux. J Biol Chem, in press.

2 Avdulov NA, Chochina SV, Daragan VA, Schroeder F, Mayo KH, Wood WG. Direct binding of ethanol to bovine serum albumin: A fluorescent and ¹³C NMR multiple relaxation study. Biochemistry 35:340–347;1996.

3 Avdulov NA, Chochina SV, Igbavboa U, Warden C, Schroeder F, Wood WG. Lipid binding to sterol carrier protein-2 is inhibited by ethanol. Biochim Biophys Acta 1437:37–45; 1999.

4 Avdulov NA, Chochina SV, Igbavboa U, Wood WG. Cholesterol efflux to high density lipoproteins and apolipoprotein A-I phosphatidylcholine complexes is inhibited by ethanol: Role of apolipoprotein structure and cooperative interaction of phosphatidylcholine and cholesterol. Biochemistry 39:10599–10606;2000.

5 Avdulov NA, Chochina SV, Myers-Payne SC, Hubbell T, Igbavboa U, Schroeder F, Wood WG. Expression and lipid binding of sterol carrier protein-2 and liver-fatty acid binding protein: Differential effects of ethanol in vivo and in vitro. In: Riemersma RA, Armstrong R, Kelly RW, Wilson R, eds. Essential Fatty Acids and Eicosanoids: Invited Papers from the Fourth International Congress. Champaign, AOCS Press, 324–327;1998.

6 Baum CL, Reschly EJ, Gayen AK, Groh ME, Schadick K. Sterol carrier protein-2 overexpression enhances sterol cycling and inhibits cholesterol ester synthesis and high density lipoprotein cholesterol secretion. J Biol Chem 272:6490–6498;1997.

7 Brouillette CG, Anantharamaiah GM. Structural models of human apolipoprotein A-I. Biochim Biophys Acta 1256:103–129;1995.

8 Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. Alcohol and blood lipids: The Cooperative Phenotyping Study. Lancet ii:153–155;1977.

9 Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211–228;1995.

10 Fielding CJ, Fielding PE. Intracellular cholesterol transport. J Lipid Res 38:1503–1521;1997.

11 Frohlich JJ. Effects of alcohol on plasma lipoprotein metabolism. Clin Chim Acta 246:39–49;1996.

12 Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol: Beverage consumption and cardiovascular mortality. Clin Chim Acta 237:155–187; 1995.

13 Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 33:737–744; 1992.

14 Hojnacki JL. Alcohol's influence on plasma lipoproteins: A nonhuman primate model. Nutr Res 14:1241–1295;1994.

15 Klatsky AL. Epidemiology of coronary heart disease: Influence of alcohol. Alcohol Clin Exp Res 18:88–96;1994.

16 Lieber CS. The metabolism of alcohol. Sci Am 234:25–33;1976.

17 Mendez AJ. Monensin and brefeldin A inhibit high density lipoprotein-mediated cholesterol efflux from cholesterol-enriched cells: Implications for intracellular cholesterol transport. J Biol Chem 270:5891–5900;1995.

18 Mendez AJ. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res 38:1807–1821;1997.

19 Myers-Payne SC, Fontaine RN, Loeffler A, Pu L, Rao AM, Kier AB, Wood WG, Schroeder F. Effects of chronic ethanol consumption on sterol transfer proteins in mouse brain. J Neurochem 66:313–320;1996.

20 Paulussen RJA, Veerkamp JH. Intracellular fatty-acid binding proteins. In: Hilderson HJ, ed. Subcellular Chemistry: Intracellular Transfer of Lipid Molecules. New York, Plenum Press, 175–226;1990.

21 Pignon J, Bailey NC, Baraona E, Lieber CS. Fatty acid-binding protein: A major contributor to the ethanol-induced increase in liver cytosolic proteins in the rat. Hepatology 7:865–871;1987.

22 Rao MN, Liu Q-H, Seef LB, Strader DB, Marmillot PR, Lakshman MR. High density lipoproteins from human alcoholics exhibit impaired reverse cholesterol transport function. Metabolism, in press.

23 Rimm EB, Williams P, Fosher K, Criqui H, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: Meta-analysis of effects on lipids and haemostatic factors. Br Med J 319:1523–1528;1999.

24 Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: Integration of old and new observations provides new insights. J Lipid Res 40:781–796;1999.

25 Salem N. Alcohol, fatty acids, and diet. Alcohol Health Res World 13:211–218;1989.

26 Schroeder F, Frolov AA, Murphy EJ, Atshaves BP, Pu L, Wood WG, Foxworth WB, Kier AB. Recent advances in membrane cholesterol domain dynamics and intracellular cholesterol trafficking. Proc Soc Exp Biol Med 213:150–177;1996.

27 Schroeder F, Myers-Payne SC, Billheimer JT, Wood WG. Probing the ligand binding sites of fatty acid and sterol carrier proteins: Effects of ethanol. Biochemistry 34:11919–11927;1995.

28 Srivastava LM, Vasisht S, Agarwal DP, Goedde HW. Relation between alcohol intake, lipoproteins and coronary heart disease: The interest continues. Alcohol Alcohol 29:11–24; 1994.

29 Sun GY, Zhang J-P, Lin T-A. Effects of acute and chronic ethanol administration on the poly-phosphoinositide signaling activity in brain. In: Alling C, Diamond I, Leslie SW, Sun GY, Wood WG, eds. Alcohol, Cell Membranes, and Signal Transduction in Brain. New York, Plenum Press, 205–218;1993.

30 Wood WG, Rao AM, Igbavboa U, Semotuk M. Cholesterol exchange and lateral cholesterol pools in synaptosomal membranes of pair-fed control and chronic ethanol-treated mice. Alcohol Clin Exp Res 17:345–350;1993.

31 Wood WG, Schroeder F, Hogy L, Rao AM, Nemecz G. Asymmetric distribution of a fluorescent sterol in synaptic plasma membranes: Effects of chronic ethanol consumption. Biochim Biophys Acta 1025:243–246;1990.

32 Wood WG, Schroeder F, Rao AM, Igbavboa U, Avdulov NA. Membranes and ethanol: Lipid domains and lipid-protein interactions. In: Deitrich RA, Erwin VG, eds. Pharmacological Effects of Ethanol on the Nervous System. Boca Raton, CRC Press, 13–27;1996.

33 Woodford JK, Colles SM, Myers-Payne SC, Billheimer JT, Schroeder F. Sterol carrier protein-2 stimulates intermembrane sterol transfer by direct membrane interaction. Chem Phys Lipids 76:73–84;1995.

34 Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway. J Biol Chem 275:23807–23813; 2000.

35 Zhao Y, Sparks DL, Marcel YL. Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts. J Biol Chem 271:25145–25151;1996.

Cholesterol Distribution in the Golgi Complex of DITNC1 Astrocytes Is Differentially Altered by Fresh and Aged Amyloid β-Peptide-(1–42)*

Urule Igbavboa‡, Justine M. Pidcock‡, Leslie N. A. Johnson‡, Todd M. Malo‡, Ann E. Studniski‡, Su Yu§, Grace Y. Sun§, and W. Gibson Wood‡¶

From the ‡Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center and the Department of Pharmacology, University of Minnesota School of Medicine, Minneapolis, Minnesota 55417 and the §Department of Biochemistry, University of Missouri, Columbia, Missouri 65211

The Golgi complex plays an important role in cholesterol trafficking in cells, and amyloid β-peptides (Aβs) alter cholesterol trafficking. The hypothesis was tested that fresh and aged Aβ-(1–42) would differentially modify Golgi cholesterol content in DINTC1 astrocytes and that the effects of Aβ-(1–42) would be associated with the region of the Golgi complex. Two different methods were used to determine the effects of Aβ-(1–42) on Golgi complex cholesterol. Confocal microscopy showed that fresh Aβ-(1–42) significantly increased cholesterol and that aged Aβ-(1–42) significantly reduced cholesterol content in the Golgi complex. Isolation of the Golgi complex into two fractions using density gradient centrifugation showed effects of aged Aβ-(1–42) similar to those observed with confocal microscopy but revealed the novel finding that fresh Aβ-(1–42) had opposite effects on the two Golgi fractions suggesting a specificity of Aβ-(1–42) perturbation of the Golgi complex. Phosphatidylcholine-phospholipase D activity, cell membrane cholesterol, and apolipoprotein E levels were associated with effects of fresh Aβ-(1–42) on cholesterol distribution but not with effects of aged Aβ-(1–42), arguing against a common mechanism. Extracellular Aβ-(1–42) targets the Golgi complex and disrupts cell cholesterol homeostasis, and this action of Aβ-(1–42) could alter cell functions requiring optimal levels of cholesterol.

Several different lines of evidence point to a potentially important but not well understood interaction between Alzheimer's disease (AD)[1] and cholesterol (for reviews, see Refs. 1–4). Apolipoprotein E4, a protein that binds and transports cholesterol and other lipids, has been identified as a risk factor for familial and sporadic AD (5, 6). Patients on specific inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase have a lower risk of developing AD as compared with individuals not taking those drugs (7, 8). A metabolite of brain cholesterol, (24S)-hydroxycholesterol, was elevated in cerebral spinal fluid of AD patients compared with control subjects (9).

Amyloid β-peptide (Aβ), the main component of neuritic plaques seen in brains of AD patients, interacts with cholesterol. This interaction is reciprocal. Cholesterol levels modulate amyloid precursor protein and Aβ synthesis (10–13). Conversely Aβ alters cholesterol dynamics. Cholesterol modulates the actions of Aβ on brain membrane fluidity (14–16). Aβ species (25–35, 1–40, and 1–42) increased the internalization of apolipoprotein E (apoE) complexed with cholesterol into neurons (17). Aβ-(1–42) increased apoE levels in astrocytes (18). Cholesterol efflux from rat hippocampal neurons to cyclodextrin was enhanced by Aβ-(1–40), and these results were attributed to redistribution of cholesterol to the plasma membrane (19). The Golgi complex plays an important role in cholesterol trafficking (20, 21), and Aβ could act on cholesterol homeostasis in the Golgi complex. Chemical inhibitors known to act on the Golgi complex alter cholesterol trafficking (20). Furthermore it has been shown that phosphatidylcholine-phospholipase D (PC-PLD) contributes to regulation of cholesterol efflux and that PC-PLD is associated with the Golgi complex (20–24). The Aβ peptide fragment 25–35 increased PLD activity in LA-N-2 cells (25). The effects of Aβ on cholesterol in the Golgi complex may also be dependent on whether Aβ is fresh or aged. Recently it was reported that oligomeric Aβ-(1–40), but not monomeric Aβ-(1–40), stimulated release of cholesterol, phospholipids, and GM1 ganglioside from neurons (26). Aged Aβ-(1–40), but not fresh Aβ-(1–40), preferentially binds cholesterol as compared with fatty acids or phosphatidylcholine (27) that might enhance removal of lipids from cell compartments. Fresh Aβ-(1–40) was reported to be located in the hydrophobic area of synaptic plasma membrane, whereas Aβ-(1–40) aged for 48 h was intercalated adjacent to the phospholipid polar head group region (28).

The current study tested the hypotheses that Aβ-(1–42) modifies Golgi complex cholesterol homeostasis in astrocytes and that the effects of Aβ-(1–42) were dependent on whether Aβ-(1–42) was fresh or aged. Gel electrophoresis of fresh Aβ-(1–42) and Aβ-(1–42) aged for 48 h showed that aged Aβ-(1–42) consisted of ~74% of the protein as a tetramer, whereas the fresh Aβ-(1–42) showed only 11% of the protein as a tetramer (28), and such structural differences could alter the behavior of Aβ. The effects of Aβ-(1–42) on Golgi complex cholesterol could involve activity of PC-PLD, and this possible action of Aβ-(1–

[1] The abbreviations used are: AD, Alzheimer's disease; Aβ, amyloid β-peptide; apo, apolipoprotein; PC, phosphatidylcholine; PLD, phospholipase D; NBD-cholesterol, 22-(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino-23,24-bisnor-5-cholen-3-β-ol); PBS, phosphate-buffered saline; BODIPY TR ceramide, N-((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3α,4α-diaza-s-indacene-3-yl)phenoxy)acetyl)sphingosine; GM1, II³NeuAc-GgOse₄Cer (where GgOse₄Cer is gangliotetraosyl ceramide); Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

42) was examined. In addition, it has been reported that apoE levels were increased in astrocytes treated with aged Aβ-(1–42) (18), and such effects might alter cholesterol distribution in cells. ApoE levels also were determined. Experiments were conducted using fresh and aged Aβ-(1–42) in immortalized DITNC1 astrocytes (29). Two different methods were used to determine the effects of Aβ-(1–42) on Golgi cholesterol content of astrocytes: 1) confocal microscopy using the fluorescent cholesterol analogue NBD-cholesterol and a fluorescent marker for the Golgi complex, BODIPY TR ceramide (30); and 2) isolation of the Golgi complex into two different fractions thought to represent different regions of the Golgi complex using sucrose density gradient centrifugation (31, 32). The results presented herein provide new insights into interaction of Aβ and cholesterol. We show that fresh Aβ-(1–42) has a strikingly different effect on cholesterol levels in the Golgi complex of astrocytes as compared with aged Aβ-(1–42). Incubation of astrocytes with fresh Aβ-(1–42) significantly increased cholesterol levels, whereas aged Aβ-(1–42) significantly reduced cholesterol levels in the Golgi complex as shown by fluorescent probes and confocal microscopy. The reverse peptide Aβ-(42–1), either fresh or aged, did not alter Golgi complex cholesterol levels, which argues against a nonspecific action of Aβ-(1–42). Isolation of the astrocyte Golgi complex into different fractions revealed the novel finding that the effects of fresh Aβ-(1–42) on cholesterol content were opposite on the two Golgi fractions, whereas aged Aβ-(1–42) had effects similar to those observed with confocal microscopy. PC-PLD activity, cell membrane cholesterol, and apoE levels of astrocytes were associated with effects of fresh Aβ-(1–42) on cholesterol levels but not with effects of aged Aβ-(1–42), suggesting different mechanisms for actions of fresh and aged Aβ-(1–42) on Golgi complex cholesterol. Our data suggest that extracellular Aβ-(1–42) specifically targets the Golgi complex and disrupts cholesterol homeostasis.

EXPERIMENTAL PROCEDURES

Materials—NBD-cholesterol (22-(*N*-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino-23,24-bisnor-5-cholen-3-β-ol), BODIPY TR ceramide, and the Amplex® Red phosphatidylcholine-specific phospholipase D (A-12219) assay kit were obtained from Molecular Probes (Eugene, OR). Aβ-(1–42) and Aβ-(42–1) were purchased from Bachem California Inc. (Torrance, CA). Fetal bovine serum was obtained from HyClone (Logan, UT). UDP-[6-^{3}H]galactose was purchased from Amersham Biosciences. The Aβ-(1–42) enzyme-linked immunosorbent assay kit (catalogue no. 17711) was obtained from Immuno-Biological Laboratories (Minneapolis, MN). All other chemicals unless specifically mentioned were purchased from Sigma.

Cell Culture—DITNC1 rat astrocytes were purchased from American Type Culture Collection (Manassas, VA). These cells have been shown to have the phenotypic characteristics of type 1 astrocytes (29). Astrocyte cells were incubated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 5% glutamate for 2 days until confluence and maintained at 37 °C in 5% CO$_2$ and at 90% relative humidity. The cells at 80–85% confluence were treated with medium containing 1% lipoprotein-deficient serum replacing the 10% fetal bovine serum and incubated for 16 h prior to experimentation. All experiments were done using confluent astrocytes.

Incubation of Cells with Fluorescent Labeled Probes and Aβ-(1–42)—Astrocytes were grown on Lab-Tek™ chamber slides, incubated with NBD-cholesterol (8 μM) for 1 h, and then washed three times with 1 ml of phosphate-buffered saline (PBS). Fresh Aβ-(1–42) (1 μM) or Aβ-(1–42) (1 μM) preincubated for 48 h (aged) was added to cells and incubated for different time periods (30, 60, and 120 min). We have reported previously that incubation of Aβ-(1–42) for 48 h resulted in ∼74% of the peptide in a tetrameric form (28). In some experiments the reverse peptide Aβ-(42–1) (fresh or aged for 48 h) was incubated with cells. Following incubation with Aβ, cells were rinsed three times with PBS, and the Golgi marker BODIPY TR ceramide (2 μM) was added and incubated with the cells for 1 h. Cells were then washed with PBS, fixed with 4% paraformaldehyde, and mounted for confocal microscopy using Gel/Mount (Biomeda Corp., Foster City, CA).

Laser Scanning Confocal Microscopy—Confocal fluorescence imaging was performed on an Olympus Fluoview laser scanning confocal imaging system (Olympus America Inc., New York). Images were captured using multiple photomultiplier tubes regulated by Fluoview 2.0 software (Olympus). Excitation of the fluorescent probes was accomplished using 15-milliwatt krypton-argon lasers with 5-milliwatt output. An Olympus BX 50 fluorescent microscope was used to capture the images using an oil immersion objective. NBD-cholesterol was excited at 488 nm, and emission was recorded at 540 nm. BODIPY TR ceramide was excited at 568 nm, and emission was recorded at 598 nm. The captured images for the red and green channels were merged and appeared yellow, which is indicative of colocalization. Red and green are additive, generating yellow to orange in RGB (red-green-blue) color space (33). Quantitative analysis of the colocalization of NBD-cholesterol and BODIPY TR ceramide was determined by image processing using MetaMorph imaging system V4.3 from Universal Imaging Corp. (Downingtown, PA) as described previously (33, 34) and expressed as percent colocalization.

Isolation of Golgi Fractions—Isolation of the Golgi complex was accomplished using sucrose density gradient centrifugation (32). Confluent astrocytes were treated with fresh and aged Aβ-(1–42) as described above. Cells were harvested and washed twice with PBS. The cells were suspended in G buffer (10 mM Tris-HCl, 0.25 M sucrose, 2 mM MgCl$_2$, pH 7.4) containing 10 mM CaCl$_2$. Leupeptin and phenylmethylsulfonyl fluoride were added to the cell suspension to inhibit proteolytic enzymes prior to homogenization. The cells were homogenized in a Potter-type homogenizer with 20–30 strokes using a serrated homogenizing pestle. The homogenate was centrifuged at 5,000 × *g* for 10 min. The pellet was suspended and homogenized in 1.4 M sucrose and overlayered with 0.8, 1.0, and 1.2 M sucrose gradients in ultracentrifuge tubes. Samples were then centrifuged at 95,000 × *g* for 2.5 h in a SW28 rotor in a Beckman L8–70 ultracentrifuge. Each interface was carefully removed, diluted with G buffer, and centrifuged in an SS34 rotor at 45,900 × *g* for 20 min. Each pellet was suspended in buffer and used for the experiments. Protein concentrations of the fractions were determined using the Bradford assay. Cholesterol content in each fraction was determined enzymatically in a microassay using a diagnostic kit from Roche Molecular Biochemicals (35) and procedures reported by our laboratory (36–38).

Galactosyltransferase Activity—A marker enzyme of the Golgi complex is galactosyltransferase, and activity of this enzyme was measured using procedures reported previously (32, 39). The incubation mixture contained 7 mg/ml ovalbumin, 2 mM ATP, 200 mM MgCl$_2$, 0.2% Triton X-100, and 50 mM Tris-HCl (pH 6.8). The reaction was initiated by adding [^{3}H]UDP-galactose to samples and incubated for 30 min, and the reaction was stopped by adding ice-cold 24% trichloroacetic acid. The precipitate was pelleted at 20,800 × *g* and washed three times with 12% trichloroacetic acid. Samples were solubilized in 5% SDS, and disintegrations/min were counted using a scintillation counter.

PC-PLD Activity—PC-PLD activity of control astrocytes and astrocytes that had been incubated with either fresh or aged Aβ-(1–42) for different time periods (30, 60, 90, and 120 min) was quantified using the Amplex Red PC-PLD assay kit (Molecular Probes). The intensity of the Amplex Red complex formed was measured in a fluorescence microplate reader (Spectra Max Gemini XS, Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 542 nm and an emission wavelength of 590 nm.

Measurement of Aβ-(1–42)—Quantitative determination of Aβ-(1–42) in the G1 and G2 fractions was carried out using an enzyme-linked immunosorbent assay kit from Immuno-Biological Laboratories. This kit uses a solid phase sandwich enzyme-linked immunosorbent assay protocol with anti-human Aβ-(38–42) rabbit IgG as primary antibody in a precoated plate and horseradish peroxidase-conjugated anti-human Aβ-(11–28) mouse IgG as secondary conjugated antibody. Briefly, standards and test samples were diluted in a buffer consisting of 1% bovine serum albumin and 0.05% Tween 20 in PBS. Test samples as well as sample and reagent blanks were added to the precoated plate and incubated overnight at 4 °C. After binding, the wells were washed (seven times) prior to adding conjugated secondary antibody and incubated for 1 h at 4 °C. After washing (nine times), the chromogen containing tetramethylbenzidine was added and incubated for 30 min at room temperature. Color reaction was terminated by the stop solution, and measurement was performed at 450 nm using a Packard Fusion AlphaScreen microplate analyzer (Packard Instrument Co.). In each assay, a standard curve was constructed after subtracting absorbance of the test sample blank. Data for test samples were converted to ng of Aβ-(1–42)/mg of protein.

ApoE Isolation—Media of control cells and cells treated with either

| NBD Cholesterol | BODIPY TR Ceramide | Colocalization |

FIG. 1. **Localization of cholesterol in the Golgi complex of astrocytes incubated with fresh and aged Aβ-(1–42) for 120 min.** Shown are confocal images of control astrocytes labeled with NBD-cholesterol (*panel A, green*) and BODIPY TR ceramide (*panel B, red*). Colocalization is shown in *panel C*. Shown are confocal images of astrocytes treated with fresh Aβ-(1–42), NBD-cholesterol (*panel D, green*), and BODIPY TR ceramide (*panel E, red*). Colocalization is shown in *panel F*. Shown are confocal images of astrocytes treated with aged Aβ-(1–42), NBD-cholesterol (*panel G, green*), and BODIPY TR ceramide (*panel H, red*). Colocalization is shown in *panel I*.

fresh or aged Aβ-(1–42) were removed, and phenylmethylsulfonyl fluoride was added as a protease inhibitor. The media were centrifuged at $800 \times g$ for 5 min, and the resulting supernatant was treated with 15% trichloric acid to precipitate protein, washed with cold methanol, dried, and kept at -20 °C for later use. Cells were harvested with trypsin/EDTA, and protein values were determined using the Bradford method with ovalbumin standards. Cells were treated with lysing buffer containing 8 M urea, 5% SDS, and 5% β-mercaptoethanol. For Western blot analysis of lysates and conditioned media, 1 μl of 1 M dithiothreitol and 1 μl of 0.2% bromphenol solution was added to every 50 μl of lysing buffer before use, and samples were kept at 70 °C for 30 min. 100–200 μg of protein were electrophoresed on a 7.5% SDS, Tricine, HCl precast gel (Bio-Rad), and proteins were transferred to a nitrocellulose membrane and incubated with monoclonal mouse anti-rat apoE (1:250) from BD Laboratory (San Diego, CA). Horseradish peroxidase-conjugated goat anti-mouse IgG (1:20,000) was used as a secondary antibody (Pierce). Immunoreactivity was visualized with SuperSignal West Pico Chemiluminescent substrate (Pierce). Band density was quantitated by densitometry using the Eagle Eye II video system and EagleSight software (Stratagene, La Jolla, CA).

RESULTS

Aβ-(1–42) Modifies Cholesterol Distribution in the Golgi Complex as Revealed by Confocal Microscopy—Experiments in this study tested the hypothesis that Aβ-(1–42) would modify cholesterol distribution in the Golgi complex of astrocytes and that the effects of Aβ-(1–42) on cholesterol distribution would be dependent on whether Aβ-(1–42) was fresh or aged. Two different methods were used to determine cholesterol distribution in the Golgi complex. 1) A fluorescent cholesterol analogue, NBD-cholesterol, and a fluorescent marker for the Golgi complex, BODIPY TR ceramide, were used and imaged with confocal microscopy; and 2) sucrose density gradient centrifugation

was used to isolate two different fractions of the Golgi complex, and cholesterol levels were determined enzymatically.

BODIPY TR ceramide, NBD-cholesterol, and confocal microscopy were used to initially examine the effects of fresh and aged Aβ-(1–42) on Golgi cholesterol content of astrocytes. Cells were incubated with Aβ-(1–42) for different time periods (30, 60, and 120 min). Cell viability as measured by trypan blue was not altered by incubation of cells with fresh or aged Aβ-(1–42) for 120 min. Means ± S.E. of the percentage of viable cells for control astrocytes, astrocytes incubated with fresh Aβ-(1–42), and astrocytes incubated with aged Aβ-(1–42) were 96.83 ± 0.58, 94.2 ± 1.5, and 97.83 ± 0.6, respectively. Confocal images of colocalization of NBD-cholesterol and BODIPY TR ceramide in control astrocytes and astrocytes incubated with fresh and aged Aβ-(1–42) for 120 min are shown in Fig. 1. *Panel C* shows colocalization of the two fluorescent probes in control astrocytes. It can be seen in *panel F* that colocalization was greater in astrocytes treated with fresh Aβ-(1–42), whereas aged Aβ-(1–42) (*panel I*) reduced colocalization as compared with control astrocytes and astrocytes incubated with fresh Aβ-(1–42). Analysis of colocalization data using MetaMorph software and expressed as percent colocalization shows that fresh Aβ-(1–42) ($p \leq 0.001$) increased colocalization in the Golgi complex of astrocytes as compared with control astrocytes (38 *versus* 23%) at the 120-min incubation period (Fig. 2). The percent colocalization of the fluorescent probes was significantly ($p \leq 0.01$) less when astrocytes were incubated with aged Aβ-(1–42) (15 *versus* 23%) for 120 min as compared with control astrocytes (Fig. 2). Shorter incubation times with Aβ-(1–42) did not significantly alter colocalization, although it can be seen in Fig. 2

FIG. 2. **Percent colocalization of BODIPY TR ceramide and NBD-cholesterol in astrocytes incubated with fresh and aged Aβ-(1–42) for different time periods and astrocytes incubated with Aβ-(42–1) for 120 min.** Quantitative measurements of colocalization of NBD-cholesterol and BODIPY TR ceramide were determined using MetaMorph software and expressed as percent colocalization. Data are means ± S.E. ($n = 3$ separate experiments). *, $p \leq 0.01$; **, $p \leq 0.001$ as compared with control astrocytes.

FIG. 3. **Changes in the distribution of cholesterol in the Golgi complex of astrocytes incubated with fresh and aged Aβ-(1–42).** Astrocytes were incubated with Aβ-(1–42) for 120 min after which time cells were harvested, and the Golgi complex was isolated using sucrose density centrifugation as described under "Experimental Procedures." The G1 fraction is the band at the 0.8–1.0 M sucrose gradient, and the G2 fraction is the band at the 1.0–1.2 M sucrose gradient. Cholesterol was determined enzymatically, and data are expressed as percentage of control. Values are means ± S.E. ($n = 3$). *, $p \leq 0.001$; **, $p \leq 0.0001$ as compared with control fractions.

that fresh Aβ-(1–42) was increasing colocalization and aged Aβ-(1–42) was reducing colocalization at the shorter incubation times. Colocalization was not altered by a lower concentration (1 nmol) of fresh Aβ-(1–42) or aged Aβ-(1–42). Means ± S.E. of percent colocalization of NBD-cholesterol and BODIPY TR ceramide were 23.71 ± 3.7, 25.82 ± 4.7, and 23.33 ± 2.1 for control astrocytes, astrocytes incubated with fresh Aβ-(1–42), and astrocytes incubated with aged Aβ-(1–42), respectively. To determine whether the effects of Aβ-(1–42) were specific and not attributable to a nonspecific perturbation of the Golgi complex we incubated astrocytes for 120 min with the reverse peptide Aβ-(42–1) that was either fresh or aged for 48 h. Neither fresh nor aged Aβ-(42–1) had an effect on the percent colocalization of BODIPY TR ceramide and NBD-cholesterol when compared with control astrocytes or with each other (Fig. 2).

UDP-galactosyltransferase Activity and Fluorescence of BODIPY TR Ceramide in Golgi Complex Fractions—Confocal microscopy revealed that Aβ-(1–42) altered the colocalization of NBD-cholesterol and BODIPY TR ceramide, a marker for the Golgi complex, and these data were interpreted as Aβ-(1–42) altering Golgi cholesterol levels. The Golgi complex is heterogenous in structure and function and may not be equally affected by Aβ-(1–42). To further define the effects of fresh and aged Aβ-(1–42) on cholesterol distribution in the Golgi complex of astrocytes, the Golgi complex was isolated using sucrose density centrifugation, and two different fractions were obtained that are thought to represent different regions of the Golgi complex (32): 1) the light Golgi fraction (G1), which is the band at the 0.8–1.0 sucrose gradient interface; and 2) the Golgi fraction 2 (G2), which is the band at the 1.0–1.2 sucrose gradient interface. Enrichment of UDP-galactosyltransferase activity and fluorescence of BODIPY TR ceramide have been used previously as markers for the Golgi complex (30, 32, 40, 41), and these markers were used in the present study. The means ± S.E. of UDP-galactosyltransferase activity (nmol/30 min/mg of protein) in astrocyte homogenate, G1 fraction, and G2 fraction were 0.019 ± 0.004, 2.751 ± 0.086, and 1.972 ± 0.129, respectively. UDP-galactosyltransferase activity was significantly higher ($p < 0.01$) in the G1 fraction as compared with the G2 fraction and was several orders of magnitude

higher in both the G1 and G2 fractions in contrast to the homogenate. Enrichment of UDP-galactosyltransferase activity in the G1 fraction as compared with the G2 fraction has been reported previously (32). BODIPY TR ceramide, a fluorescent Golgi complex marker, had a similar distribution in the G1 and G2 astrocyte fractions as was observed for UDP-galactosyltransferase activity (data not shown).

Aβ-(1–42) Modifies Cholesterol Distribution in the Golgi Complex Fractions as Revealed by Sucrose Density Centrifugation—We next examined the effects of Aβ-(1–42) on cholesterol content of the G1 and G2 fractions. The effects of fresh and aged Aβ-(1–42) on cholesterol in the G1 fraction were similar to effects we observed using confocal microscopy. Fresh Aβ-(1–42) significantly ($p < 0.0001$) increased cholesterol, whereas aged Aβ-(1–42) significantly ($p < 0.001$) reduced cholesterol in the G1 fraction (Fig. 3). The magnitude of effects of fresh Aβ-(1–42) on cholesterol in the G1 fraction was greater than that of aged Aβ-(1–42), and these results were similar to those observed with confocal microscopy.

Fig. 3 shows that fresh Aβ-(1–42) had an opposite effect on cholesterol in the G2 fraction as compared with the G1 fraction. There was a significant ($p < 0.001$) reduction in cholesterol in the G2 fraction when incubated with fresh Aβ-(1–42). On the other hand, aged Aβ-(1–42) had a similar effect on cholesterol in the G2 fraction as observed in the G1 fraction, resulting in a significant ($p < 0.001$) reduction in cholesterol (Fig. 3). Differences in effects of fresh and aged Aβ-(1–42) on cholesterol levels in the Golgi complex could be attributed to differences in amounts of fresh and aged Aβ-(1–42) that reach the Golgi complex. Levels of fresh Aβ-(1–42) were higher in the G1 and G2 fractions (0.21 ± 0.03 and 0.22 ± 0.1 ng/mg of protein, respectively) as compared with aged Aβ-(1–42) in the G1 and G2 fractions (0.11 ± 0.05 and 0.16 ± 0.04 ng/mg of protein, respectively). These differences in Aβ-(1–42) levels, however, were not statistically significant.

Both colocalization data and data of the G1 fraction showed that fresh Aβ-(1–42) increased cholesterol and aged Aβ-(1–42) reduced cholesterol in the Golgi complex of astrocytes. The cell membrane is enriched in cholesterol and could be a source of cholesterol in cells treated with fresh Aβ-(1–42). Table I shows

TABLE I

Total cholesterol, free cholesterol, and the molar ratio of free to total cholesterol in cell membranes of astrocytes incubated with fresh and aged Aβ-(1–42)

Treatment	Total cholesterol	Free cholesterol	Free/total
	μmol/mg protein	*μmol/mg protein*	
Control	9.59 ± 0.13	8.26 ± 0.65	0.87 ± 0.07
Fresh Aβ-(1–42)	6.37 ± 0.19[a]	5.84 ± 0.36[b]	0.92 ± 0.02
Aged Aβ-(1–42)	7.97 ± 0.24[b,c]	7.32 ± 0.26[c]	0.92 ± 0.06

[a] $p \leq 0.01$ as compared with control.
[b] $p \leq 0.05$ as compared with control.
[c] $p \leq 0.05$ as compared with fresh Aβ-(1–42), $n = 3$.

that fresh Aβ-(1–42) significantly reduced both total and free cholesterol in the cell membrane as compared with control astrocytes. Total cholesterol was reduced by 34% and free cholesterol by 30% when treated with fresh Aβ-(1–42). Aged Aβ-(1–42) also significantly reduced total and free cholesterol (17 and 11%, respectively) in the cell membrane (Table I), but effects were much less than those observed for fresh Aβ-(1–42). The ratio of free cholesterol to total cholesterol was used as an estimate of esterified cholesterol. Data in Table I show that the ratios were similar among the three groups and did not differ significantly. It also was noted that cholesterol content of the astrocyte homogenate fraction did not differ among the three groups.

Aβ-(1–42) Inhibits PC-PLD Activity—PC-PLD has been shown to be involved in regulating cholesterol efflux from cells (42) and in release of secretory vesicles from the Golgi complex (23, 43), and an isoform of PC-PLD has been reported to be associated with the Golgi complex (20, 22). To begin to address a potential mechanism whereby Aβ-(1–42) alters cholesterol content in the Golgi complex, we examined the effects of fresh and aged Aβ-(1–42) on activity of PC-PLD in astrocytes. Fig. 4 (*panels A and B*) reveals that fresh and aged Aβ-(1–42) significantly ($p < 0.001$) inhibited PC-PLD activity at each incubation time period. There was a small diminution of effects of Aβ-(1–42) on PC-PLD activity with increasing incubation time. PC-PLD activity was significantly ($p < 0.001$) higher after 90 and 120 min of incubation *versus* 30 min of incubation for fresh Aβ-(1–42) and after 120 min for aged Aβ-(1–42) (Fig. 4, *panels A and B*). The effects of fresh Aβ-(1–42) on PC-PLD activity were consistent with the increase in cholesterol in the Golgi complex, but PC-PLD activity does not explain the effects of aged Aβ-(1–42) on Golgi complex cholesterol.

Effects of Fresh and Aged Aβ-(1–42) on ApoE Levels in Astrocytes—It has been reported previously that Aβ-(1–42) increased astrocyte activation, increased levels of apoE and apoJ in the cell, and reduced levels of the two apolipoproteins in the medium (18). The effects of activation were proposed to primarily involve apoE and its receptors. Changes in Aβ-(1–42)-induced levels of apoE and release of apoE could have an effect on cholesterol content by sequestering cholesterol in the cell. Fig. 5 (*inset*) shows that apoE under reducing conditions can be seen as approximately a 34-kDa monomer, and this finding is consistent with apoE expression in astrocytes (18). Fresh Aβ-(1–42) significantly ($p \leq 0.01$) increased apoE levels by 32% in astrocytes as compared with control cells (Fig. 5). Aged Aβ-(1–42) appeared to reduce apoE levels, but this difference was not statistically significant when compared with control cells. ApoE was not detected in the conditioned media from control and Aβ-(1–42)-treated cells (data not shown).

DISCUSSION

Several different lines of evidence show that Aβ and cholesterol interact (for reviews, see Refs. 4 and 44–47). This interaction is reciprocal given that cholesterol modulates expression of amyloid precursor protein and Aβ (10–13) and cholesterol


FIG. 4. **Fresh and aged Aβ-(1–42) inhibit PC-PLD activity in astrocytes.** Astrocytes were incubated with fresh Aβ-(1–42) (*panel A*) and aged Aβ-(1–42) (*panel B*) for different time periods (30, 60, 90, and 120 min) after which time cells were harvested as described under "Experimental Procedures." Cells were placed in 96-well plates, and PC-PLD was determined using the Amplex Red PC-specific PLD assay kit (Molecular Probes). Fluorescence intensity was measured with a microplate reader using an excitation wavelength of 542 nm and an emission wavelength of 590 nm. Values are means ± S.E. ($n = 3$). *, $p < 0.001$ as compared with control cells; +, $p < 0.001$ as compared with 30-min incubation time.

dynamics such as cholesterol trafficking are affected by Aβ (15, 17–19). The Golgi complex plays an important role in cholesterol trafficking (21, 48), and we proposed that Aβ-(1–42) would alter cholesterol trafficking in the Golgi complex and that the effects of Aβ-(1–42) would be dependent on whether the peptide was fresh or aged. Two different methods, confocal microscopy and isolation of the Golgi complex by sucrose density centrifugation, were used to test the hypothesis that fresh and aged Aβ-(1–42) would have different effects on cholesterol in the Golgi complex of astrocytes. Results of this study showed

FIG. 5. **Fresh Aβ-(1–42) but not aged Aβ-(1–42) increases apoE levels in astrocytes.** Cells were treated as described under "Experimental Procedures." Levels of apoE were quantitated from Western blots. Data of cells treated with Aβ-(1–42) are the levels of apoE relative to control cells and are the means ± S.E. from three to four independent experiments. The *inset* shows a Western blot from a representative sample. *, $p \leq 0.01$ as compared with control. *Ctrl*, control.

that Aβ-(1–42) modifies cholesterol distribution in the Golgi complex of astrocytes. However, the effects of Aβ-(1–42) on cholesterol distribution were dependent on whether Aβ-(1–42) was fresh or aged. Fresh Aβ-(1–42) increased cholesterol content in the Golgi complex, and aged Aβ-(1–42) reduced cholesterol content in the Golgi complex. Moreover isolation of the Golgi complex into two fractions revealed the novel finding that fresh Aβ-(1–42) increased cholesterol in the G1 fraction and reduced cholesterol in the G2 fraction. Aged Aβ-(1–42) reduced cholesterol in both fractions. PC-PLD activity, cell membrane cholesterol, and apoE levels were associated with effects of fresh Aβ-(1–42) on cholesterol levels but not with effects of aged Aβ-(1–42), arguing against a common mechanism.

Aβ-(1–42) altered cholesterol distribution in the Golgi complex of astrocytes. Maximal effects of both fresh and aged Aβ-(1–42) were observed after 120 min of incubation and a peptide concentration of 10^{-6} M. Shorter incubation times modified cholesterol levels in the Golgi complex, but these effects were not significantly different. An Aβ-(1–42) concentration of 10^{-9} M did not modify cholesterol levels. Aβ-(1–42)-induced changes in Golgi complex cholesterol levels were not simply attributable to a nonspecific perturbation of the Golgi complex or cell viability. The reverse peptide Aβ-(42–1), either fresh or aged, did not alter Golgi complex cholesterol levels compared with control astrocytes. Viability of cells did not differ among the control and cells treated with fresh or aged Aβ-(1–42).

Fresh Aβ-(1–42) increased astrocyte cholesterol in the G1 fraction by 59% but reduced cholesterol in the G2 fraction by 29%. Earlier work has indicated that the G1 fraction may represent the *trans*-Golgi region and that the G2 fraction is representative of the *medial* and *cis* regions (31, 32). Fresh Aβ-(1–42) may stimulate movement of cholesterol from the *cis* and *medial* regions of the Golgi to the *trans*-Golgi region. Mechanisms of anterograde intra-Golgi transport have focused on cisternal maturation/progression and vesicular/tubular transport, but the principal mechanism of intra-Golgi transport including transport of lipids has not been resolved (for a review, see Ref. 49). Movement of cholesterol from the G2 to the G1 fraction induced by fresh Aβ-(1–42) would account for only 29% of the increase in cholesterol observed in the G1 fraction. Our data showing that there was a significant reduction in cholesterol content in the cell membrane of astrocytes treated with fresh Aβ-(1–42) (34%) as compared with control astrocytes

suggest that fresh Aβ-(1–42) stimulates transport of cholesterol from the cell membrane to the *trans*-Golgi region. There is evidence that cycling of lipids including cholesterol and proteins occurs between the cell surface membrane and the Golgi complex that is clathrin-independent (50, 51). It has been suggested that this cell membrane-Golgi pathway may regulate lipid raft distribution and function with recycling occurring continuously (51). Amyloid precursor protein and Aβ are associated with cholesterol-rich low density membrane domains (52–55). Extracellular Aβ that is not highly aggregated may target lipid rafts, promoting cycling of lipid rafts to the Golgi complex.

Aged Aβ-(1–42) reduced cholesterol levels in the Golgi complex but also reduced cholesterol levels in the cell membrane by 16% as compared with the 34% reduction by fresh Aβ-(1–42). The destinations and mechanisms of the cell membrane cholesterol removed by fresh and aged Aβ-(1–42) may differ. Aged Aβ-(1–42) may complex with cholesterol in the cell membrane and transport cholesterol to the cell interior. Support for this notion are data showing that indeed aged Aβ-(1–40), but not fresh Aβ-(1–40), complexed with lipids with cholesterol $\gg$ stearic acid $>$ PC (27). Once removed, the aged Aβ-(1–42)-cholesterol complex may act as a type of lipid droplet in the cell cytosol. Synucleins that had been chemically cross-linked formed oligomers within cells that complexed with lipid droplets and cell membranes (56). It is clear that fresh Aβ-(1–42) and aged Aβ-(1–42) are acting differently on cholesterol homeostasis.

Cholesterol levels were increased in the Golgi complex by incubation with fresh Aβ-(1–42), and this increase may be due in part to cycling of cholesterol from the cell membrane to the Golgi complex. We also propose that the elevation in cholesterol levels in the Golgi complex involves PC-PLD function. PC-PLD plays a role in cholesterol trafficking, it is located in the Golgi complex, and PC-PLD is also involved in vesicular trafficking from the Golgi complex (20–23). Our findings that fresh Aβ-(1–42) increased cholesterol content in the Golgi complex and inhibited activity of PC-PLD are in agreement with the purported role of PC-PLD in cholesterol trafficking. Inhibition of PC-PLD reduces cholesterol efflux (22, 42). Activation of PC-PLD enhanced the release of secretory vesicles from the *trans*-Golgi complex (43). Inhibition of PC-PLD by fresh Aβ-(1–42) may in turn reduce release of secretory vesicles with their lipid and protein cargoes. We found that fresh Aβ-(1–42) inhibited PC-PLD activity, but another study reported that the Aβ peptide fragment 25–35 increased PLD activity in LA-N-2 cells (57). Differences in effects of Aβ on PLD activity between that study and the present study may have resulted from dissimilarities in peptide structure and peptide concentration (Aβ-(1–42) at 1 μM *versus* Aβ-(25–35) at 100 μM). Inhibition of PC-PLD activity by fresh Aβ-(1–42) was in agreement with our findings that cholesterol levels were elevated in the Golgi complex in the presence of fresh Aβ-(1–42). However, we also observed that aged Aβ-(1–42) significantly inhibited PC-PLD activity but that cholesterol levels were reduced in the Golgi complex of astrocytes incubated with aged Aβ-(1–42). Both fresh and aged Aβ-(1–42) inhibit PC-PLD activity, but the mechanism of effects on cholesterol levels in the Golgi complex may differ as discussed in the preceding paragraph. Aged Aβ-(1–42) may remove cholesterol by forming complexes, whereas fresh Aβ-(1–42) induces movement of cholesterol within the Golgi complex and from the cell membrane to the Golgi complex and inhibits the recycling of cholesterol that involves PC-PLD function.

The effects of fresh Aβ-(1–42) on Golgi complex cholesterol were associated with apoE levels. Fresh Aβ-(1–42) signifi-

cantly increased apoE levels in astrocytes by ~32% as compared with control cells. On the other hand, aged Aβ-(1–42) reduced apoE levels, but this reduction did not differ significantly from that seen in control cells. Previously it was found that aged Aβ-(1–42) increased apoE levels in rat astrocytes from primary cell culture (18). In the same study it also was reported that aged Aβ-(1–42) reduced levels of apoE in the medium (18). We did not detect apoE in the media of control astrocytes and cells incubated with either fresh or aged Aβ-(1–42). Two major differences between our study and the earlier report were the incubation time of 2 *versus* 12 h and the Aβ-(1–42) concentration of 1 *versus* 10 μM, respectively. An important observation of the earlier study was that Aβ-(1–42) did not alter steady-state levels of apoE mRNA, and that may indicate that Aβ-(1–42) was not acting on transcriptional regulation but could have been acting post-translationally on apoE turnover (18). Whether the observed increase in apoE levels in astrocytes incubated with fresh Aβ-(1–42) plays a role in effects of the peptide on cholesterol in the Golgi complex is unclear. ApoE is associated with the Golgi complex (58), and changes in apoE levels may modify intracellular cholesterol distribution.

We have shown using two different methods that Aβ-(1–42) modifies the cholesterol content of the Golgi complex of astrocytes. The effects of Aβ-(1–42) on cholesterol levels were dependent on whether astrocytes were treated with fresh or aged Aβ-(1–42). Fresh Aβ-(1–42) increased cholesterol levels of the Golgi complex, whereas aged Aβ-(1–42) reduced cholesterol levels. However, the direction of effects of fresh Aβ-(1–42) on Golgi cholesterol levels was contingent on the region of the Golgi complex suggesting that fresh Aβ-(1–42) may also be acting on intra-Golgi cholesterol transport. The Golgi complex has been described as a major site for protein and lipid sorting and release of lipid rafts (59, 60). Either increasing or decreasing cholesterol levels could impact on important Golgi complex functions such as protein sorting, sphingomyelin synthesis, and lipid trafficking resulting in cellular pathophysiology. Our data suggest that the recycling of cholesterol between the cell membrane and the Golgi complex was altered and that such changes could modify membrane structure and function. Fresh Aβ may inhibit the formation of lipid rafts in the Golgi complex including caveolin-organized rafts that are transported to the plasma membrane and form caveolae. Aβ peptides are located in detergent-insoluble membrane domains that are thought to be caveolae (54, 61) and in cholesterol domains not containing caveolin (52). PC-PLD activity, cell membrane cholesterol, and apoE expression of astrocytes were associated with effects of fresh Aβ-(1–42) on Golgi complex cholesterol but not with effects of aged Aβ-(1–42), arguing against a common mechanism. There is a reciprocal synergy between Aβ and cholesterol. Changes in cholesterol content alter Aβ levels, and Aβ acts on cholesterol homeostasis. The dynamic interaction of Aβ and cholesterol that includes targeting of the Golgi complex may be an important factor that contributes to cellular dysfunction occurring with AD.

REFERENCES

1. Sparks, D. L. (1997) *Ann. N. Y. Acad. Sci.* **826**, 128–146
2. Liu, Y. (1999) *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **23**, 377–395
3. Wood, W. G., Schroeder, F., Avdulov, N. A., Chochina, S. V., and Igbavboa, U. (1999) *Lipids* **34**, 225–234
4. Wood, W. G., Eckert, G. P., Igbavboa, U., and Müller, W. E. (2003) *Biochim. Biophys. Acta* **1610**, 281–290
5. Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-Maclachlan, D. R., Alberts, M. J., Hulette, C., Crain, B., Goldgaber, D., and Roses, A. D. (1993) *Neurology* **43**, 1467–1472
6. Strittmatter, W. J., and Roses, A. D. (1996) *Annu. Rev. Neurosci.* **19**, 53–77
7. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000) *Lancet* **356**, 1627–1631
8. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000)

Arch. Neurol. **57**, 1439–1443
9. Papassotiropoulos, A., Lutjohann, D., Bagli, M., Locatelli, S., Jessen, F., Buschfort, R., Ptok, U., Bjorkhem, I., von Bergmann, K., and Heun, R. (2002) *J. Psychiatr. Res.* **36**, 27–32
10. Howlands, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B. D., Scott, R. M., and Flood, D. G. (1998) *J. Biol. Chem.* **273**, 16576–16582
11. Bodovitz, S., and Klein, W. L. (1996) *J. Biol. Chem.* **271**, 4436–4440
12. Simons, M., Keller, P., Destrooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 6460–6464
13. Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T. (2002) *J. Neurosci.* **22**, 1679–1689
14. Eckert, G. P., Cairns, N. J., Maras, A., Gattaz, W. F., and Müller, W. E. (2000) *Dement. Geriatr. Cogn. Disord.* **11**, 181–186
15. Chochina, S. V., Avdulov, N. A., Igbavboa, U., Cleary, J. P., O'Hare, E., and Wood, W. G. (2001) *J. Lipid Res.* **42**, 1292–1297
16. Kirsch, C., Eckert, G. P., and Müller, W. E. (2002) *Amyloid* **9**, 149–159
17. Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J., and Poirier, J. (1998) *J. Neurochem.* **70**, 1458–1466
18. LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., and Van Eldik, L. J. (2000) *J. Biol. Chem.* **275**, 33974–33980
19. Liu, Y., Peterson, D. A., and Schubert, D. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 13266–13271
20. Mendez, A. J. (1995) *J. Biol. Chem.* **270**, 5891–5900
21. Heino, S., Lusa, S., Somerharju, P., Ehnholm, C., Olkkonen, V. M., and Ikonen, E. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97**, 8375–8380
22. Siddhanata, A., Backer, J. M., and Shields, D. (2000) *J. Biol. Chem.* **275**, 12023–12031
23. Ktistakis, N. T., Brown, H. A., Sternweis, P. C., and Roth, M. G. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 4952–4956
24. Freyberg, Z., Bourgoin, S., and Shields, D. (2002) *Mol. Biol. Cell* **13**, 3930–3942
25. Singh, I. N., Sorrentino, G., and Kanfer, J. N. (1998) *Neurochem. Res.* **23**, 1225–1232
26. Michikawa, M., Gong, J.-S., Fan, Q.-W., Sawamura, N., and Yanagisawa, K. (2001) *J. Neurosci.* **18**, 7226–7235
27. Avdulov, N. A., Chochina, S. V., Igbavboa, U., Vassiliev, A. V., and Wood, W. G. (1997) *J. Neurochem.* **69**, 1746–1752
28. Mason, R. P., Jacob, R. F., Walter, M. F., Mason, P. E., Avdulov, N. A., Chochina, S. V., Igbavboa, U., and Wood, W. G. (1999) *J. Biol. Chem.* **274**, 18801–18807
29. Radany, E. H., Brenner, M., Besnard, F., Bigornia, V., Bishop, J. M., and Deschepper, C. F. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 6467–6471
30. Harrington, E. O., Löffler, J., Nelson, P. R., Kent, K. C., Simons, M., and Ware, J. A. (1997) *J. Biol. Chem.* **272**, 7390–7397
31. Lucocq, J. M., Berger, E. G., and Warren, G. (1989) *J. Cell Biol.* **109**, 463–474
32. Andrés, J., Diaz, M., Monteiro-Leal, L. H., and De Souza, W. (1996) *Exp. Parasitol.* **83**, 174–183
33. Atshaves, B. P., Starodub, O., McIntosh, A., Petrescu, A., Roths, J. B., Kier, A. B., and Schroeder, F. (2000) *J. Biol. Chem.* **275**, 36582–36861
34. Zhang, Z.-Q., Notermans, D. W., Sedgewick, G., Cavert, W., Wietgrefe, S., Zupanic, M., Gebhard, K., Henry, K., Boies, L., Chen, Z., Jenkins, M., Mills, R., McDade, H., Goodwin, C., Schuwirth, C. M., Danner, S. A., and Haase, A. T. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 1154–1159
35. Auerbach, B. J., Parks, J. S., and Applebaum-Bowden, D. (1990) *J. Lipid Res.* **30**, 738–742
36. Wood, W. G., Igbavboa, U., Rao, A. M., Schroeder, F., and Avdulov, N. A. (1995) *Brain Res.* **683**, 36–42
37. Rao, A. M., Igbavboa, U., Semotuk, M., Schroeder, F., and Wood, W. G. (1993) *Neurochem. Int.* **23**, 45–52
38. Wood, W. G., Rao, A. M., Igbavboa, U., and Semotuk, M. (1993) *Alcohol. Clin. Exp. Res.* **17**, 345–350
39. Sztul, E., Kaplin, A., Saucan, L., and Palade, G. (1991) *Cell* **64**, 81–89
40. Nilson, T., Pypaert, M., Hoe, M., Slusarewicz, P., Berger, E. G., and Warren, G. (1993) *J. Cell Biol.* **120**, 5–13
41. Michaelson, D., Silletti, J., Murphy, G., D'Eustachio, P., Rush, M., and Philips, M. R. (2001) *J. Cell Biol.* **152**, 111–126
42. Walter, M., Reinecke, H., Gerdes, U., Nofer, J.-R., Höbbel, G., Seedorf, U., and Assman, G. (1996) *J. Clin. Investig.* **98**, 2315–2323
43. Chen, Y.-E., Siddhanta, A., Austin, C. D., Hammond, S. M., Sung, T.-C., Frohman, M. A., Morris, A. J., and Shield, D. (1997) *J. Cell Biol.* **138**, 495–504
44. Koudinov, A. R., and Koudinova, N. V. (2001) *FASEB J.* **15**, 1858–1860
45. Pappolla, M. A., Smith, M. A., Bryant-Thomas, T., Bazan, N., Petanceska, S., Perry, G., Thal, L. J., Sano, M., and Refolo, L. M. (2002) *Free Radic. Biol. Med.* **33**, 173–181
46. Yanagisawa, K. (2002) *J. Neurosci. Res.* **70**, 361–366
47. Wood, W. G., Schroeder, F., Igbavboa, U., Avdulov, N. A., and Chochina, S. V. (2002) *Neurobiol. Aging* **23**, 685–694
48. Mendez, A. J. (1997) *J. Lipid Res.* **38**, 1807–1821
49. Marsh, B. J., and Howell, K. E. (2002) *Nat. Rev.* **3**, 789–795
50. Puri, V., Watanabe, R., Singh, R. D., Dominguez, M., Brown, J. C., Wheatley, C. L., Marks, D. L., and Pagano, R. E. (2001) *J. Cell Biol.* **154**, 535–547
51. Nichols, B. J., Kenworthy, A. K., Polishchuk, R. S., Lodge, R., Roberts, T. H., Hirschberg, K., Phair, R. D., and Lippincott-Schwartz, J. (2001) *J. Cell Biol.* **153**, 529–542
52. Hayashi, H., Mizuno, T., Michikawa, M., Haass, C., and Yanagisawa, K. (2000) *Biochim. Biophys. Acta* **1483**, 81–90
53. Maekawa, S., Sato, C., Kitajima, K., Funatsu, N., Kumanogoh, H., and Sokawa, Y. (1999) *J. Biol. Chem.* **274**, 21369–21374
54. Morishima-Kawashima, M., and Ihara, Y. (1998) *Biochemistry* **37**, 15247–15253
55. Oshima, N., Morishima-Kawashima, M., Yamaguchi, H., Yoshimura, M., Sugihara, S., Khan, K., Games, D., Schenk, D., and Ihara, Y. (2001) *Am. J.*

Pathol. **158,** 2209–2218

56. Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D. L., and Nussbaum, R. L. (2002) *J. Biol. Chem.* **277,** 6344–6352

57. Singh, I. N., Sorrentino, G., Sitar, D. S., and Kanfer, J. N. (1998) *Brain Res.* **800,** 275–281

58. Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., and Mahley, R. W. (1987) *Biochim. Biophys. Acta* **917,** 148–161

59. Fang, M., Rivas, M. P., and Bankaitis, V. A. (1998) *Biochim. Biophys. Acta* **1404,** 85–100

60. Schroeder, F., Gallegos, A. M., Atshaves, B. P., Storey, S. M., McIntosh, A. L., Petrescu, A. D., Huang, H., Starodub, O., Chao, H., Yang, H., Frolov, A., and Kier, A. B. (2001) *Exp. Biol. Med.* **226,** 873–890

61. Lee, S.-J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T., and Kosik, K. S. (1998) *Nat. Med.* **4,** 730–734

Cholesterol Efflux is Inhibited by Ethanol in Human Smooth Muscle Aortic Cells:

Differences in Sensitivity of HDL and Apolipoprotein A-I and the

Roles of Phosphatidylcholine-Phospholipase C and D

Urule Igbavboa, Justine M. Pidcock, Todd M. Malo, Leslie N. A. Johnson, and W. Gibson Wood

Geriatric Research, Education and Clinical Center, VA Medical Center,

and Department of Pharmacology, University of Minnesota School of Medicine,

Minneapolis, Minnesota 55417

b) Correspondence: Dr. W. Gibson Wood, GRECC 11G, VA Medical Center, One Veterans

Drive, Minneapolis, MN 55417. Tel.: 612-725-2051; Fax: 612-725-2084;

email: woodx002@umn.edu

ABSTRACT

Moderate alcohol consumption is associated with a reduced risk of cardiovascular morbidity and mortality. An increase in high-density lipoproteins (HDL) that are involved in cholesterol efflux are one of the factors that are thought to contribute to this reduced risk. However, HDL levels are elevated in heavy drinkers and alcoholics but their risk is not reduced. Ethanol may interfere with cholesterol efflux and experiments in this paper report on acute effects of ethanol on cholesterol efflux from human smooth muscle aortic cells (HSMAC) to HDL, apolipoprotein A-I (apoA-I) and the role of phosphatidylcholine-phospholipase C (PC-PLC) and PC-phospholipase D (PC-PLD). Both PC-PLC and PC-PLD are involved in cholesterol efflux and also acted upon by ethanol. Cholesterol efflux to HDL and apoA-I was determined in HSMAC using the fluorescent cholesterol analogue, dehydroergosterol. Ethanol significantly inhibited HDL-mediated cholesterol efflux from HSMAC. Significant effects of ethanol were seen at ethanol concentrations of 50 and 75 mM but not at 25 mM ethanol. ApoA-I was more effective in inducing sterol efflux than was HDL and significant inhibition occurred beginning at 25 mM ethanol. Ethanol stimulated activity of PC-PLD and PC-PLC but effects were greater on PC-PLD. Ethanol may promote movement of cholesterol to the plasma membrane by stimulating phospholipase C and D-induced vesicular transport. However, removal of cholesterol from the plasma membrane is inhibited by ethanol interfering with the physico-chemical interaction of HDL and particularly apoA-I with cell surface proteins. Heavy drinkers and alcoholics may be at risk with respect to acute and chronic effects of ethanol on cholesterol efflux and conversion of lipid-free apoA-I to mature HDL.

Running title: Ethanol Inhibits Cholesterol Efflux in Human Aortic Cells

Risk of coronary heart disease (CHD) morbidity and mortality is reduced by moderate alcohol consumption whereas some studies suggest that heavy alcohol consumption has little or no benefit for CHD(*1-4*). A generally accepted finding of epidemiological and experimental studies is that high-density lipoproteins (HDL) levels are increased in association with alcohol consumption {1096,1097,1204,1093, }. An increase in HDL has been proposed to be one of the potential factors involved in the protective effects of moderate alcohol consumption on CHD (*5;6*). HDL levels however, are increased in heavy drinkers but their risk of CHD is higher than that of moderate alcohol drinkers (*7-9*). An important function of HDL is removal of excess lipids including cholesterol from cells and evidence has shown that chronic and acute administration of ethanol alters lipoprotein-mediated cholesterol efflux. Cholesterol efflux was decreased in mouse macrophages incubated with HDL of human alcoholic subjects (*10*). However, it was recently reported that cholesterol efflux was stimulated from Fu5AH rat hepatoma cells to plasma of human subjects who consumed 40 g of alcohol per day for 3 weeks (*11*). Acute administration of ethanol (350 mM) increased the rate of cholesterol efflux from erythrocytes to plasma (*12*). Ethanol concentrations (25 and 50 mM) that are seen in alcoholics and heavy drinkers inhibited cholesterol efflux from rat fibroblasts to HDL and apoA-I (*13*).

Removal of lipids from cells involves several different mechanisms (e.g., membrane receptors, lipoproteins, signaling pathways, Golgi complex) that could be targets of ethanol perturbation. Ethanol for example has been reported to have a greater effect on lipid incorporation into apoA-I as compared with HDL (*13*). ApoA-I is thought to activate phosphatidylcholine-PLD (PC-PLD) and phosphatidylcholine-phospholipase C (PC-PLC) resulting in phospholipid hydrolysis and production of phosphatidic acid (PA) and

4

diacylglycerol, respectively (*14*). Both PC-PLC and PC-PLD appear to be two of the

mechanisms involved in regulating cholesterol efflux from cells (*14*). PC-PLD is of particular

importance with respect to action of ethanol because in the presence of alcohols there is a

transphosphatidylation reaction and a phosphatidylalcohol is formed and a reduction of PA

production (*15;16*). PA has been shown to stimulate cholesterol efflux (*14*). Ethanol may alter

activity of PC-PLC and PC-PLD that could impact on cholesterol efflux. Activity of PC-PLC in

hepatocytes and activity of PC-PLD in fibroblasts were enhanced by ethanol (*17;18*). Butanol

which has a membrane/buffer partition coefficient several orders of magnitude higher than

ethanol, inhibited cholesterol efflux of human fibroblasts and reduced production of phosphatidic

acid (*14*). In the same study it was shown that inhibition of PC-PLC by D 609 reduced

cholesterol efflux and it was concluded that both PC-PLD and PC-PLC play a role in cholesterol

efflux (*14*).

The purpose of the experiments reported in this paper were to determine if acute ethanol

administration altered cholesterol efflux induced by HDL and apoA-I in cells that are directly

involved in cardiovascular function. Human aortic smooth muscle cells (HASMC) were used in

this study. ApoA-I has been proposed to interact with the ATP binding cassette transporter 1

(ABC1) to remove cholesterol in contrast to HDL and HASMC are enriched in ABC1 (*19;20*).

Cholesterol efflux mediated by HDL and apoA-I may differ in response to ethanol. In addition,

effects of ethanol on activation of PC-PLC and PC-PLD activity were determined in HASMC

using an enzyme coupled assay and *N*-acetyl-3,7-dihydroxyyphenoxazine (*21*).

METHODS

Materials. ApoA-I and HDL were purchased from Calbiochem-Novabiochem Corp. (San Diego, CA). Amplex Red phosphatidylcholine-specific phospholipase C (A-12218) and phospholipase D (A-12219) assays kits were obtained from Molecular Probes (Eugene, Oregon). Human aortic smooth muscle cells and cell growth media (Smooth Muscle Cell Basal Medium (SmBM®), growth factors, trypsin/EDTA , HEPES Buffer Saline Solution (HBBS) and Trypsin Neutralizing Solution (TNS) were all obtained from Bio∗Whittaker Company (Walkersville, MD). FBS and antimytotic were obtained from HyClone, (Logan,UT). Lipoprotein deficient serum from human plasma was obtained from Sigma-Aldrich Chemicals (St. Louis, MO). 96-well plates for were purchased from USA Scientific, (Woodland, CA). L-Glutamine was obtained from Invitrogen:GibCo Corp. (Carlsbad, CA). Ethanol and all other reagents and chemicals were obtained from Sigma-Aldrich Chemicals (St. Louis, MO).

Cell Culture. Human aortic smooth muscle cells (HASMC) were grown in 25 cm^2 flask using SmBM® media and SMGM®- 2 Singlequot ®. The flasks with cells were maintained in an incubator at 37°C with 5% CO_2 . Media was replaced every 2 days. All experiments were performed with confluent cells.

Cholesterol Efflux. Confluent HASMC were preloaded with the fluorescent cholesterol analogue, dehydroergosterol (DHE) (3 μg/ml of cell culture medium) for 18 h in 0.5% lipoprotein deficient serum. DHE incubation time and concentration were determined from sampling incorporation of DHE into HASMC over 0-24 h. The optimal HDL or apoA-I concentration for our experiment was obtained by incubating the cells with different concentrations of HDL (10-40 μg of protein/ml of cell culture medium) or apoA-I for 2 h. HDL (30 μg of protein/ml of cell culture medium) was used in the cholesterol efflux experiments. In

experiments using apoA-I, 30 μg of apoA-I/ml of cell culture medium were used and this amount

is based on our recent report (*13*). Cells were incubated for a period of 30 min with 0, 25, 50, or

75 mM ethanol after which 30 μg of human plasma HDL protein/ml of medium or 30 μg of

apoA-I/ml of medium was added and cells were further incubated for 2 h. Cells were then

washed twice with HBBS, trypsinized and neutralized with TNS or serum, collected, and

centrifuged at 14,000 rpm for 1 min in an Eppendorf centrifuge (model 541 7R). The pellet

containing cells was washed twice with 1 ml PBS and homogenized in a loose-fitting

homogenizer. The protein of the homogenized samples was determined by Bradford method.

Sample (25μg protein) was placed in a quartz cuvette and DHE fluorescence intensity

determined using a LS-50B fluorimeter (Perkin-Elmer, Norwalk, CT) with the excitation

wavelength of 324 nm and emission wavelength of 376 nm.

PC-PLC and PC-PLD Assays. PC-PLC activity and PC-PLD activity in HASMC were

quantified using the Amplex red PC-PLC and PC-PLD assay kits (Molecular Probes, Eugene,

OR). Cells were incubated with ethanol (0, 25, 50, and 75 mM) for 2 h after which time cells

were then washed twice with HBBS, trypsinized and neutralized with TNS or serum, collected,

and centrifuged at 14,000 rpm for 1 min in an Eppendorf centrifuge (model 541 7R). The pellet

containing cells was washed twice with 1 ml PBS and homogenized in a loose-fitting

homogenizer and aliquots placed in 96 well-plates and the assay reagents added. The intensity of

the Amplex Red complex formed was measured after 60 min in a fluorescence microplate reader

(Spectra Max Gemini XS, Molecular Device, Sunnyvale, CA) using an excitation wavelength of

542 nm and an emission wavelength of 590 nm.

RESULTS

Incorporation of Dehydroergosterol in HASMC. DHE is a sterol occurring in yeast, it is very similar to cholesterol in its structure and function, and it has been previously used as a cholesterol analogue in several different studies of sterol dynamics REVIEWED IN (*22;23*). DHE is an ideal cholesterol analogue because the sterol is naturally fluorescent containing an endogenous fluorescent conjugated triene system in the B and C rings. DHE transport kinetics are analogous to those of cholesterol (*23-25*). The purpose of these baseline experiments was to determine optimal conditions for DHE incorporation into HASMC. Three different concentrations of DHE (1,2,3 µg/ml of media) were incubated with HASMC for 18 h. Incorporation of DHE into cells was monitored by an increase in DHE fluorescence intensity. Figure 1 shows that DHE concentration of 3 µg/ml of media produced a robust increase in fluorescence intensity compared to the two lower concentrations. Fluorescence of non-incorporated DHE in the medium was negligible. The magnitude of fluorescence intensity was dependent also on the duration of incubation of DHE with cells. Fluorescence intensity of DHE steadily increased over time plateau ng between 18 and 24 h of incubation (Figure 2).

Sterol Efflux to HDL and ApoA-I. Figure 3 shows the effects of increasing concentrations of HDL on sterol efflux from HASMC. DHE fluorescence was measured in cells following removal of HDL by centrifugation. HDL significantly removed DHE from HASMC, and this effect was maximal at 30 µg of HDL protein/ml of medium and did not change significantly when 40 µg of HDL protein/ml of medium was added (Figure 3).

There was approximately a 20% reduction in cholesterol in cells incubated with HDL alone compared with no HDL and ethanol significantly inhibited HDL-mediated cholesterol efflux from HASMC (Figure 4). Significant effects of ethanol were seen at ethanol

8

concentrations of 50 and 75 mM ($p < 0.04$) but not at 25 mM ethanol (Figure 4). Effects of ethanol at 50 and 75 mM resulted in approximately 8-10% of cholesterol being removed from cells by HDL as compared to 20% removal by HDL alone.

There was a 24% reduction in sterol in cells when incubated with apoA-I alone as compared with cells not incubated with apoA-I (Figure 5). Ethanol significantly ($p \leq 0.001$) inhibited sterol efflux beginning at a concentration of 25 mM ethanol (Figure 5). In the presence of 50 and 75 mM ethanol, there was only approximately 6% and 3% of sterol removed respectively, by apoA-I.

PC-PLD and PC-PLC Activity. Both PC-PLC and PC-PLD have been proposed to be involved in cholesterol efflux. PC-PLD was significantly stimulated by ethanol (Figure 5). There was a 2-fold increase in PC-PLD activity by 25 mM ethanol as compared to control cells. It can be seen in Figure 5 that both 50 and 75 mM ethanol significantly ($p \leq 0.001$) increased PC-PLD activity as compared to control cells but this effect was not as large as observed for 25 mM ethanol.

Activity of PC-PLC was significantly ($p \leq 0.03$) increased by 25 mM ethanol as compared to the control cells resulting in a 16% increase in activity of the enzyme (Figure 6). PC-PLC activity was higher in the presence of 50 or 75 mM ethanol as compared to control but these differences were not significant.

DISCUSSION

Experiments in this paper tested the hypothesis that ethanol at concentrations observed in heavy drinkers and alcoholics would alter cholesterol efflux induced by HDL and apoA-I in vascular cells. ApoA-I was used because recent evidence suggest that apoA-I may directly interact with cell surface receptors and that ethanol has a differential effect on apoA-I as compared with HDL (*13;20*). In addition, effects of ethanol on PC-PLC activity and PC-PLD activity were examined. Both phospholipases have been previously shown to be involved in regulation of cholesterol efflux and acted upon by ethanol. We found that acute administration of ethanol inhibited cholesterol efflux from human smooth muscle aortic cells to HDL and apoA-I. Cholesterol efflux induced by apoA-I was more sensitive to effects of ethanol as compared with HDL. PC-PLD activity and PC-PLC activity were increased by ethanol with the greatest effect seen on PC-PLD activity.

Acute administration of ethanol inhibited cholesterol efflux induced by HDL and apoA-I from human smooth muscle aortic cells. ApoA-I had a greater effect on cholesterol efflux and was more sensitive to effects of ethanol compared with HDL. Significant inhibition of cholesterol efflux occurred at an ethanol concentration of 25 mM in the presence of apoA-I versus 50 mM in the presence of HDL. Differences in the magnitude of effects of ethanol on HDL and apoA-I may be due to direct effects of ethanol on those structures and interaction with cell surface proteins. Previously it has been reported that ethanol inhibited incorporation of cholesterol into apoA-I-PC complexes but did not alter incorporation of cholesterol into HDL (*13*). There is also evidence that lipid efflux to apoA-I involves proteins at the cell surface such as ABC-1 transporter and caveolin (*20;26*). Recently, it was reported that cholesterol efflux from HASMC to apoA-I was derived from membrane microdomains enriched in caveolin (*27*).

10

Ethanol has been reported to decrease the level of caveolin in astrocytes (28) that might interfere with lipid efflux.

PC-PLC and PC-PLD have been shown to contribute to the regulation of cholesterol efflux (14;29). PC-PLC hydrolyzes PC producing diacylglycerol and phosphocholine and PC-PLD also hydrolyzes PC resulting in phosphatidic acid (PA) and choline. ApoA-I and HDL_3 are thought to activate these two phospholipases (14;29) that in turn induces transport of cholesterol to the plasma membrane. In the presence of primary alcohols and PC-PLD a transphosphatidylation reaction occurs with production of a phosphatidylalcohol instead of PA. Cholesterol efflux has been reported to be inhibited by n-butanol in fibroblasts (14;29). We found that ethanol increased activity of both PC-PLC and PC-PLD with the largest effect observed for PC-PLD. The increase in activities of PC-PLD and PC-PLC by ethanol are in agreement with earlier reports in studies of hepatocytes and fibroblasts (17;18). An ethanol concentration of 25 mM had a greater effect on activity of both phospholipases as compared with 50 and 75 mM ethanol particularly with respect to PC-PLD. This concentration dependent effect of ethanol could be due to inhibition of upstream effectors of PC-PLD and PC-PLC such as protein kinase C, G-protein-coupled receptors, and apoA-I (29).

There is evidence that the Golgi complex is important in cholesterol efflux and that an isoform of PC-PLD may be associated with the Golgi complex (30-33). Ethanol may increase transport of cholesterol from the Golgi complex to the plasma membrane by stimulating activity of PC-PLD. It has been shown in fibroblasts that 40 mM and 80 mM ethanol significantly reduced cholesterol content in the Golgi complex as compared to control cells (34). If cholesterol is transported to the plasma membrane, efflux of cholesterol from the plasma membrane may be hindered by ethanol-induced perturbation of apoA-I, HDL and cell surface proteins. However, it

11

has been reported that 1-butanol (135 and 200 mM) inhibited release of nascent secretory vesicles of the Golgi complex that was attributed to a reduction of PA formation (*32;35*). The Golgi complex structure was disassembled in the study using 200 mM butanol (*32*). 1-Butanol is more hydrophobic than ethanol, the membrane/buffer partition coefficient of 1-butanol is markedly higher as compared with ethanol (1.52 versus 0.096), and higher 1-butanol concentrations were used in that study compared with the ethanol study that could contribute to differences between effects of ethanol and butanol on the Golgi complex.

HDL and apoA-I induced cholesterol efflux in HASMC was inhibited by ethanol. Ethanol has also been shown to have similar effects on cholesterol efflux in rat fibroblasts (*13*). Conversely, cholesterol efflux was increased in rat hepatoma cells incubated with plasma from human subjects who had consumed ethanol (30-40 g etoh/day/for 2-3 weeks) (*11;36*). Alcohol amounts used in those studies were considered moderate. On the other hand , HDL isolated from alcoholic patients were less efficient in removing cholesterol from mouse macrophages (*10*). Ethanol has both an acute effect and a chronic effect on cholesterol efflux. In the present study, effects of acute administration of ethanol at amounts observed in heavy drinkers and alcoholics inhibited cholesterol efflux. A potential consequence of elevated blood alcohol levels is that conversion of lipid-free apoA-I to mature HDL may be hindered. Moderate alcohol consumption stimulated cholesterol efflux whereas HDL of alcoholic patients were less efficient in removing cholesterol from cells. Heavy drinkers and alcoholics may be at greater risk for vascular disease as a result of both the acute and chronic effects of ethanol on regulation of cholesterol in cells.

REFERENCES

1. Eagles, C. J. and Martin, U. (1998) *J. Clin. Pharm. Ther. 23*, 1-9.

2. Klatsky, A. L. (1999) *Alcohol Res. Health 23*, 15-23.

3. Rimm, E. B., Williams, P., Fosher, K., Criqui, H., and Stampfer, M. J. (1999) *Br. Med. J. 319*, 1523-1528.

4. Sesso, H. D. and Gaziano, J. M. (1999) *Curr. Opin. Nephrol. Hypertens 8*, 353-357.

5. Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., and Zukel, W. J. (1977) *Lancet ii*, 153-155.

6. Criqui, M. H., Cowan, L. D., Tyroler, H. A., Bangdiwala, S., Heiss, G., and Wallace, R. B. (1987) *Am. J. Epidemiol. 126*, 629-637.

7. Frohlich, J. J. (1996) *Clinica Chimica Acta 246*, 39-49.

8. Goldberg, D. M., Hahn, S. E., and Parkes, J. G. (1995) *Clinica Chimica Acta 237*, 155-187.

9. Hojnacki, J. L. (1994) *Nutrition Research 14*, 1241-1295.

10. Rao, M. N., Liu, Q.-H., Seef, L. B., Strader, D. B., Marmillot, P. R., and Lakshman, M. R. (2000) *Metabolism 49*, 1406-1410.

11. van der Gaag, M. S., van Tol, A., Vermunt, S. H. F., Scheek, L. M., Schaafsma, G., and Hendriks, H. F. J. (2001) *J. Lipid Res. 42*, 2077-2083.

12. Daniels, C. K. and Goldstein, D. B. (1982) *Mol. Pharmacol. 21*, 694-700.

13. Avdulov, N. A., Chochina, S. V., Igbavboa, U., and Wood, W. G. (2000) *Biochemistry 39*, 10599-10606.

14. Walter, M., Reinecke, H., Gerdes, U., Nofer, J.-R., Höbbel, G., Seedorf, U., and Assman, G. (1996) *J. Clin. Invest. 98*, 2315-2323.

15. Heller, M. (1978) *Adv. Lipid Res. 16*, 267-326.

16. Moehren, G., Gustavsson, L., and Hoek, J. B. (1994) *J. Biol. Chem. 269*, 838-848.

17. Pittner, R. A. and Fain, J. N. (1992) *Biochim Biophys Acta 1133*, 316-320.

18. Kiss, Z. and Anderson, W. B. (1990) *J. Biol. Chem. 265*, 7345-7350.

19. Wang, N., Silver, D. L., Costet, P., and Tall, A. R. (2000) *J. Biol. Chem. 275*, 33053-33058.

20. Fielding, P. E., Nagao, K., Hakamata, H., Chimini, G., and Fielding, C. J. (2000) *Biochemistry 39*, 14113-14200.

21. Zhou, M., Diwu, Z., Panchuk-Voloshina, N., and Haugland, R. P. (1997) *Anal Biochem 253*, 162-168.

22. Schroeder, F., Frolov, A. A., Murphy, E. J., Atshaves, B. P., Pu, L., Wood, W. G., Foxworth, W. B., and Kier, A. B. (1996) *Proc. Soc. Exp. Biol. Med. 213*, 150-177.

23. Mukherjee, S., Zha, X., Tabas, I., and Maxfield, F. R. (1998) *Biophys J 75*, 1915-1925.

24. Kier, A. B., Sweet, W. D., Cowlen, M. S., and Schroeder, F. (1986) *Biochim Biophys Acta 861*, 287-301.

25. Nemecz, G., Fontaine, R. N., and Schroeder, F. (1988) *Biochim Biophys Acta 943*, 511-521.

26. Lawn, R. M., Wade, D. P., Garvin, M. R., Wang, X., Schwartz, K., Porter, J. G., Seilhamer, J. J., Vaughan, A. M., and Oram, J. F. (1999) *J. Clin. Invest. 104*, 2-3.

27. Fielding, P. E., Russel, J. S., Spencer, T. A., Hakamata, H., Nagao, K., and Fielding, C. J. (2002) *Biochemistry 41*, 4929-4937.

28. Megias, L., Guerri, C., Fornas, E., Azorin, I., Bendala, E., Sancho-Tello, M., Duran, J. M., Tomas, M., Gomez-Lechon, M. J., and Renau-Piqueras, J. (2000) *Int. J. Dev. Biol. 44*, 209-221.

29. Haidar, B., Mott, S., Boucher, B., Lee, C. Y., Marcil, M., and Genest, Jr. J. (2001) *J. Lipid Res. 42*, 249-257.

30. Mendez, A. J. (1995) *J. Biol. Chem. 270*, 5891-5900.

31. Heino, S., Lusa, S., Somerharju, P., Ehnholm, C., Olkkonen, V. M., and Ikonen, E. (2000) *Proc. Natl. Acad. Sci. U. S. A. 97*, 8375-8380.

32. Siddhanata, A., Backer, J. M., and Shields, D. (2000) *J. Biol. Chem. 275*, 12023-12031.

33. Ktistakis, N. T., Brown, H. A., Sternweis, P. C., and Roth, M. G. (1995) *Proc. Natl. Acad. Sci. U. S. A. 92*, 4952-4956.

34. Igbavboa, U., Kiss, Z., and Wood, W. G. (2001) *FASEB J. 15*, A529.

35. Chen, Y.-E., Siddhanta, A., Austin, C. D., Hammond, S. M., Sung, T.-C., Frohman, M. A., Morris, A. J., and Shield, D. (1997) *J. Cell. Biol. 138*, 495-504.

36. Senault, C., Betoulle, D., Luc, G., Hauw, P., Rigaud, D., and Fumeron, F. (2000) *Nutr. Metab. Cardiovasc. Dis. 10*, 63-69.

FIGURE LEGENDS

Figure 1: Incorporation of DHE into HASMC. In all experiments, confluent cells were used. DHE (3 μg/mL of cell culture medium) was added to cells, and at each time point, cells were processed and the DHE fluorescence was measured as described in the Methods section. Data are means ± SEM (n = 3). (Inset) Confluent HASMC were incubated with different concentrations of DHE for 18 h. Cells were then harvested and processed, and DHE fluorescence was measured. Data are means ± SEM (n = 3).

Figure 2: HDL-mediated efflux of DHE from HASMC. Confluent cells were incubated with 3 μg of DHE/mL of cell culture medium for 18 h. Cells were then washed twice using DHE-free medium and incubated with increasing concentrations of human plasma HDL for 2 h. Cells were then harvested and processed and DHE fluorescence was measured. Data are means ± SEM (n = 3). * p ≤ 0.02 as compared with no HDL.

Figure 3: Ethanol Inhibits HDL-Mediated DHE Efflux from HASMC. Confluent HASMC were incubated with 3 μg of DHE/mL of cell culture medium for 18 h. Cells were then washed twice using DHE-free medium and incubated for 30 min with 25, 50, or 75 mM ethanol or no ethanol, after which 30 μg of human plasma HDL protein/mL of medium was added and cells were incubated for 2 h. Cells were then harvested and processed, and DHE fluorescence was measured. The control cells contained DHE but were not incubated with HDL or ethanol. Data are means ± SEM (n = 4). * p ≤ 0.04 compared with HDL and no ethanol; ** indicates p ≤ 0.0001 compared with control.

Figure 4: Ethanol Inhibits ApoA-I Mediated DHE Efflux from HASMC. Confluent HASMC were incubated with 3μg of DHE/mL of cell culture medium for 18 h. Cells were then washed twice using DHE-free medium and incubated for 30 min with 25, 50, 0r 75 mM ethanol or no

ethanol, after which 30 μg of human plasma apoA-I /mL of medium was added and cells were incubated for 2 h. Cells were then harvested and processed, and DHE fluorescence was measured. The control cells contained DHE but were not incubated with apoA-I or ethanol. Data are means ± SEM (n = 3). $^*p \leq 0.001$ as compared to apoA-I no ethanol; $^{**}p \leq 0.0002$ as compared to control no apoA-I.

Figure 5: Effects of Ethanol on PC-PLD Activity in HASMC. Confluent cells were incubated with different concentrations of ethanol for 2 h after which cells were harvested as described in Methods section. 20 μg of cells were placed in 96 well plates and PC-PLD determined using the Amplex® red PC-specific PLD assay kit. Samples were incubated for 60 min at 37°C. Fluorescence was measured with a microplate reader using an excitation wavelength of 542 nm and emission wavelength of 590 nm. Data are means ± SEM (n = 4). $^*p \leq 0.004$ as compared to 0 ethanol; $^{**}p \leq 0.0001$ as compared to each condition.

Figure 6: Effects of Ethanol on PC-PLC Activity in HASMC. Confluent cells were incubated with different concentrations of ethanol for 2 h after which cells were harvested as described in Methods section. 20 μg of cells were placed in 96 well plates and PC-PLC determined using the Amplex® red PC-specific PLC assay kit. Samples were incubated for 60 min at 37°C. Fluorescence was measured with a microplate reader using an excitation wavelength of 542 nm and emission wavelength of 590 nm. Data are means ± SEM (n = 4). $^*p \leq 0.02$ as compared to each condition.

HIGH DENSITY LIPOPROTEIN AND APOLIPOPROTEIN A-I INDUCED CHOLESTEROL EFFLUX IS INHIBITED BY ETHANOL IN HUMAN SMOOTH MUSCLE AORTIC CELLS: ROLES OF LIPOPROTEIN STRUCTURE AND THE GOLGI COMPLEX

Igbavboa U, Pidcock JM, Malo TM, Studniski AE, Johnson LNA, Wood WG

Department of Pharmacology, University of Minnesota School of Medicine, GRECC, VAMC, Minneapolis, MN 55455 USA

Woodx002@umn.edu

BACKGROUND/PURPOSE: Moderate alcohol consumption is associated with a reduced risk of cardiovascular morbidity and mortality. An increase in high-density lipoproteins (HDL) that are involved in cholesterol efflux are one of several factors that are thought to contribute to this reduced risk. However, HDL levels are elevated in heavy drinkers and alcoholics but their risk is not reduced. Ethanol may interfere with cholesterol efflux from cells and we examined acute effects of ethanol on cholesterol efflux from human aortic smooth muscle cells (HASMC) to HDL, apolipoprotein A-I (apoA-I) and the roles of ethanol perturbation of HDL, apoA-I and the Golgi complex. **METHODS:** Cells were incubated with different concentrations of ethanol and cholesterol efflux to HDL and apoA-I was determined using a fluorescent labeled sterol. Steady-state polarization of tryptophan residues of apoA-I was examined and cholesterol complexing with HDL and apoA-I was studied using fluorescent labeled sterol. Confocal microscopy and density gradient centrifugation were used to examine effects of ethanol on the Golgi complex. **RESULTS:** Ethanol significantly inhibited HDL-mediated cholesterol efflux from cells. Significant effects of ethanol were seen at ethanol concentrations of 50 and 75 mM but not at 25 mM ethanol. ApoA-1 was more effective in inducing sterol efflux than was HDL and significant inhibition occurred at 25 mM ethanol. Also ethanol had a greater inhibitory effect on cholesterol complexing with apoA-I as compared with HDL. Ethanol directly altered cholesterol in the Golgi complex as revealed by confocal microscopy showing a reduction of cholesterol. To further understand effects of ethanol on the Golgi complex, we used density gradient centrifugation to separate the Golgi complex regions. The *trans*-Golgi region was more susceptible to effects of ethanol compared with the *cis*-medial-Golgi region. **CONCLUSION:** An overriding conclusion is that ethanol at concentrations observed in problem drinkers and alcoholics (e.g., an individual consuming either 6 beers, or 6 one shots of whiskey, or 6 glasses of wine) has a profound and multifaceted effect on cellular regulation of cholesterol involving HDL, apoA-I and the Golgi complex. Ethanol reduces the ability of the cell to remove cholesterol. This finding has several important implications. The clinical determination of cholesterol is based on amount of cholesterol in the serum (total cholesterol, LDL-cholesterol, HDL-cholesterol) but not the amount of cholesterol in cells. Cholesterol content in cells of problem drinkers and alcoholics may be elevated as compared to control subjects and such a difference would not be detected by routine clinical assays for cholesterol. Cholesterol is essential for the normal function of cells. Ethanol-induced changes in cell cholesterol content could have profound pathophysiological consequences on cell function.

Igbavboa, U., Kiss, Z., and Wood, W. G. Cholesterol in Golgi complex is modified by ethanol as revealed by confocal microscopy. *FASEB Journal*, 2001, *15*, A529.

Ethanol inhibits cholesterol efflux from cells to HDL and apolipoprotein-AI-PC complexes (<I>Biochemistry</I>,39, 10599-10606,2000). The Golgi complex is involved in regulation of cholesterol efflux and ethanol may interfere with this regulation. We examined effects of ethanol on cholesterol content of the Golgi complex in NIH 3T3 fibroblasts using confocal microscopy and densitometric analysis. The fluorescent cholesterol analogue, NBD-cholesterol and the fluorescent labeled probe for Golgi, BODIPY TR ceramide were used. Ethanol modified cholesterol content in Golgi but the direction of effects was concentration dependent. Ethanol at a concentration of 40 mM significantly increased cholesterol in the Golgi complex however, 80 mM ethanol significantly decreased cholesterol content. Zinc, that previously has been shown to stimulate cholesterol transport, significantly decreased cholesterol content in the Golgi complex and abolished the stimulatory effects of 40 mM ethanol. Reduction of cholesterol by 80 mM ethanol was furthered increased by zinc. Effects of 40 mM ethanol on cholesterol content of Golgi are consistent with our data showing that 25 and 50 mM ethanol inhibited cholesterol efflux from cells to HDL and apoA-I-PC complexes. Ethanol could disrupt formation of lipid rafts in the Golgi complex resulting in an accumulation of cholesterol. Alternatively, ethanol could stimulate transport of cholesterol from other organelles to the Golgi complex. Both 80 mM ethanol and zinc singularly and combined reduced cholesterol in Golgi. It is unclear if the mechanisms for those effects of ethanol and zinc are the same or are different. Ethanol modifies cholesterol homeostasis in the Golgi complex and such modification could certainly could impact on lipid and protein sorting and sphingomyelin synthesis.

HDL AND APOLIPOPROTEIN AI-INDUCED CHOLESTEROL EFFLUX IS
INHIBITED BY ETHANOL IN HUMAN SMOOTH MUSCLE AORTIC
CELLS: ROLES OF PHOSPHOLIPASES C AND D. U. Igbavboa; J. M. Pidcock;
W.G. Wood. Geriatric Research, Education and Clinical Center, VA Medical Center,
and Department of Pharmacology, University of Minnesota School of Medicine,
Minneapolis, Minnesota 55417.

Molecular mechanisms of ethanol-induced inhibition of cholesterol efflux are not well-understood. Cholesterol is removed from cells by HDL and lipid-free and lipid-poor apolipoproteins. The ATP binding cassette transporter is thought to play a role in cholesterol efflux by direct interaction with lipid free apoA-I but not HDL. There is also evidence that the Golgi complex contributes to regulation of cholesterol efflux that may involve activity of PC-phospholipase C (PC-PLC) and PC-phospholipase D (PC-PLD). Effects of ethanol on cholesterol efflux may differ depending on whether efflux is elicited by HDL or apoA-I and ethanol could disrupt activity of PC-PLD or PC-PLC. These hypotheses were examined using human smooth muscle aortic cells. Ethanol significantly inhibited HDL-mediated cholesterol efflux from cells. Significant effects of ethanol were seen at ethanol concentrations of 50 and 75 mM ($p < 0.04$) but not at 25 mM ethanol.ApoA-1 was more effective in inducing sterol efflux than was HDL and inhibition occurred at 25 mM ethanol. Both PC-PLD and PC-PLC activity were affected by ethanol and ethanol directly altered cholesterol in the Golgi complex as revealed by confocal microscopy. Ethanol-induced perturbation of the Golgi complex in addition to effects on cholesterol dynamics may affect other important Golgi functions such as formation and release of secretory vesicles including lipid rafts. This work was supported by a grant from the US Army Medical Research and Material Command (DAMD 32001) and the Department of Veterans Affairs.

Family name of registered participant:	Wood	Appendix 7
First name of registered participant:	W. Gibson	
E-mail of registered participant:	Woodx002@umn.edu	

This line should be filled correctly to accept abstract !!!!!!!!!!!!!!!!!!!!!!

I prefer presentation oral*, or poster*, no preference*, poster format (90x120cm), (please delete type of the presentation which You don`t prefere)

Write number of topic (1-7): S10

Title of the presentation: Use CAPITAL LETTERS

HDL AND APOLIPOPROTEIN AI-INDUCED CHOLESTEROL EFFLUX IS INHIBITED BY ETHANOL IN HUMAN SMOOTH MUSCLE AORTIC CELLS: ROLES OF PHOSPHOLIPASE D AND THE GOLGI COMPLEX

Authors (presenting (registered) author should have an asterisk inserted after name):

Urule Igbavboa, Justine M. Pidcock, Todd M. Malo, Ann E. Studniski, Leslie N.A. Johnson and W. Gibson Wood

Full mailing address. Add e-mail address of the presenting (registered) author:

Geriatric Research, Education and Clinical Center, 11G, VA Medical Center, and Department of Pharmacology, University of Minnesota School of Medicine, Minneapolis, Minnesota 55417 woodx002@umn.edu

Text of the abstract: (at most till the end of the page, including References, 350 words)

Moderate alcohol consumption is associated with a reduced risk of cardiovascular morbidity and mortality. An increase in high-density lipoproteins (HDL) that are involved in cholesterol efflux are one of several factors that are thought to contribute to this reduced risk. However, HDL levels are elevated in heavy drinkers and alcoholics but their risk is not reduced. Ethanol may interfere with cholesterol efflux from cells and we examined acute effects of ethanol on cholesterol efflux from human aortic smooth muscle cells (HASMC) to HDL, apolipoprotein A-I (apoA-I) and the roles of phosphatidylcholine-phospholipase D (PC-PLD) and the Golgi complex. There is evidence that the Golgi complex is important in cholesterol efflux and that an isoform of PC-PLD may be associated with the Golgi complex. Ethanol significantly inhibited HDL-mediated cholesterol efflux from cells. Significant effects of ethanol were seen at ethanol concentrations of 50 and 75 mM ($p < 0.04$) but not at 25 mM ethanol. ApoA-1 was more effective in inducing sterol efflux than was HDL and inhibition occurred at 25 mM ethanol. PC-PLD activity was affected by ethanol and ethanol directly altered cholesterol in the Golgi complex as revealed by confocal microscopy. Ethanol may promote movement of cholesterol to the plasma membrane by stimulating PC-PLD induced vesicular transport. However, removal of cholesterol from the plasma membrane may be inhibited by ethanol interfering with the physico-chemical interaction of HDL and particularly apoA-I with cell surface proteins. Heavy drinkers and alcoholics may be at risk with respect to acute and chronic effects of ethanol on cholesterol efflux and conversion of lipid-free apoA-I to mature HDL. Ethanol-induced perturbation of the Golgi complex in addition to effects on cholesterol dynamics may affect other important Golgi functions such as formation and release of secretory vesicles including lipid rafts.

Alcohol and Alcoholism, 38, 474, 2003.